



10031311 1150602

JCO3 Rec'd PCT/PTO 15 JAN 2002

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)		ATTORNEY'S DOCKET NUMBER X-12591
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/031311
INTERNATIONAL APPLICATION NO. PCT/US00/17864	INTERNATIONAL FILING DATE 21 July 2000 (21.07.00)	PRIORITY DATE CLAIMED 29 July 1999 (29.07.99)
TITLE OF INVENTION: SEROTONERGIC BENZOTHIOPHENES		
APPLICANT(S) FOR DO/EO/US: Karin Briner, Timothy Paul Burkholder, Richard Gerard Conway, Brian Eugene Cunningham, Don Richard Finley, Lawrence Joseph Heinz, Cynthia Darshini Jesudason, Daniel Timothy Kohlman, Sidney Xi Liang, and Yao-Chang Xu		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information: 		

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">10/031311</div>		INTERNATIONAL APPLICATION NO. <div style="font-weight: bold;">PCT/US00/17864</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold;">X-12591</div>	
17. <input checked="" type="checkbox"/> The following fees are submitted: <div style="margin-left: 20px;"> BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$750.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00 </div>				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	19 -20=	0	X \$18.00	\$	
Independent claims	5 -3=	2	X \$84.00	\$ 168.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$ 168.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 1,058.00	
Processing fee of \$130.00 for furnishing English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 1,058.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <div style="text-align: right;">\$40.00 per property</div>				\$	
TOTAL FEES ENCLOSED =				\$ 1,058.00	
				Amount to be refunded	\$
				charged	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 05-0840 in the amount of \$1,058.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION/1104 LILLY CORPORATE CENTER INDIANAPOLIS, INDIANA 46285 <div style="margin-top: 10px;"> <i>January 9, 2002</i> DATE </div> <div style="margin-top: 10px;"> 45,165 REGISTRATION NUMBER </div>			<div style="font-size: 1.2em;">  SIGNATURE </div> <div style="margin-top: 10px;"> R. Craig Tucker NAME </div> <div style="margin-top: 10px;"> (317) 433-9829 TELEPHONE NUMBER </div>		<div style="font-size: 1.5em;">  25885 PATENT TRADEMARK OFFICE </div>

1003110/0313412
531 Rec'd PCT/PT 15 JAN 2002

"Express Mail" mailing label number EL230529959US Date of Deposit Jan. 15, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

QUEEN THOMAS
Printed Name

Queen Thomas
Signature

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The accompanying Application

Applicants : BRINER, Karin, et al.
For : SEROTONERGIC BENZOTHIOPHENES
Docket No. : X-12591

ENTRY INTO U.S. NATIONAL PHASE UNDER PCT CHAPTER II
PRELIMINARY AMENDMENT PURSUANT TO 37 C.F.R. §1.121 AND REMARKS
PURSUANT TO 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D. C. 20231
Sir:

This is a preliminary amendment accompanying a PCT Chapter II filing of PCT International Application No. PCT/US00/17864. Prior to examination of the above-identified application, entry of the following amendments is respectfully requested.

AMENDMENTS

IN THE SPECIFICATION:

Please amend page 1 of the specification to add a new first paragraph, under the title, as follows in clean form:

This application claims priority to U.S. Provisional application 60/146,185, filed 29 July 99 and US Provisional application 60/172,784, filed 20 December 99.

X-12591

-2-

IN THE CLAIMS:

Please amend Claim 6 to read:

6. (Amended) The method of Claim 3 where the mammal is human.

Please add the following new Claims:

7. (new) The method of Claim 4 where the mammal is human.
8. (new) The method of Claim 5 where the mammal is human.
9. (new) A method for the treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I of Claim 1, or a pharmaceutically acceptable acid addition salt thereof.
10. (new) The method of Claim 9 where the mammal is human.
11. (new) A compound of Claim 1 where A is attached at the 7-position of the benzofuran nucleus.
12. (new) A compound according to Claim 11 where Q is hydrogen.
13. (new) A compound according to Claim 12 where R⁶ is C₁-C₄ alkyl and R⁵, R^{5'}, R⁷ and R^{7'} are each hydrogen.
14. (new) A compound according to Claim 13 where R^{6'} is hydrogen, and R⁶ and the benzofuran core are in the cis configuration with regard to each other.
15. (new) A compound according to Claim 13 where R⁶ is methyl.
16. (new) A compound according to Claim 13 where R^{6'} is methyl.

X-12591

-3-

17. (new) A compound according to Claim 11 where one of $R^{5'}$ and Q, or $R^{6'}$ and Q, taken together with the carbon atoms to which they are attached form a double bond.

18. (new) A compound according to Claim 17 where of $R^{5'}$ and Q, taken together with the carbon atoms to which they are attached form a double bond, $R^{6'}$ is C_1 - C_4 alkyl, and $R^{6'}$ is methyl.

19. (new) A compound according to Claim 18 which is 3,3-dimethyl-4-(6-fluorobenzothien-7-yl)-1,2,3,6-tetrahydropyridine.

REMARKS

The amendment to the Specification merely adds a specific claim of priority to the priority documents to the present International Application, U.S. Provisional Application 60/146185 and 60/172,784, as required under 35 U.S.C. 119(e)(1).

The amendment to Claim 6 and new Claims 7 and 8 are merely mechanical amendments to eliminate the multiple dependency of the original claims.

New Claims 9-19 more particularly point out and distinctly claim the subject matter Applicants regard as their invention. No new matter is added to the specification.

New Claims 9 and 10 are drawn to another preferred method of treatment using the presently claimed novel compounds, and finds support throughout the specification and specifically at page 3, lines 15-30, especially lines 25-26.

New Claims 11-19 are drawn to various preferred embodiments of the inventive family of compounds and are supported throughout the specification, and especially as follows:

New Claim 11, see page 8, lines 23-24;

New Claim 12, see page 8, line 27;

New Claim 13, see page 8, line 27 and page 10, line 17;

X-12591

-4-

New Claim 14, see page 6, lines 5-6, and example 4;

New Claim 15, see page 9, line 25, and example 4;

New Claim 16, see page 10, line 15-16, and example 8;


New Claim 17, see page 8, lines 28-31, and example 1;

New Claim 18, see page 8, lines 28-29, page 9, lines 24 and 27, page 10, lines 22-23, and example 2;

New Claim 19, see example 3.

A mark-up copy of Claim 6 showing the changes made in this present amendment is enclosed on a separate sheet as required by 37 C.R.F. 1.121. A clean copy of the entire claim set as amended herewith is also enclosed for the Examiner's convenience. Entry of the forgoing amendments prior to substantive examination is respectfully requested.

Respectfully submitted,



R. Craig Tucker
Attorney for Applicants
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division/DC1104
Lilly Corporate Center
Indianapolis, Indiana 46285

10031311-01506912
10/031311
531 Rec'd PCT/PTL 15 JAN 2002

X-12591

-5-

MARKED-UP COPY OF AMENDED CLAIMS


6. The [A] method of [any of] Claim[s] 3[, 4, or 5] where the mammal is human.

X-12591

-6-

We Claim:

1. The compounds of Formula I:



I

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or - C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

X-12591

-7-

R^5 , R^6 , and R^7 are independently hydrogen or C_1 - C_4 alkyl;

Q is hydrogen;

$R^{5'}$ is hydrogen or methyl, provided that $R^{5'}$ may be methyl only when R^5 is other than hydrogen, or $R^{5'}$ and Q taken together with the carbon atoms to which they are attached form a double bond;


$R^{6'}$ is hydrogen or methyl, provided that $R^{6'}$ may be methyl only when R^6 is other than hydrogen, or $R^{6'}$ and Q taken together with the carbon atoms to which they are attached form a double bond;

$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and


b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$ may be other than hydrogen.



X-12591

-8-

2. A pharmaceutical formulation which comprises, in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of Formula I:



I

where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;


R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxy carbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

X-12591

-9-

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:


a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

X-12591

-10-

3. A method for increasing activation of the 5-HT_{2C} receptor in mammals, comprising administering to a mammal in need of such activation a pharmaceutically effective amount of a compound of Formula I:



where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;


R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

X-12591

-11-

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:


a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

X-12591

-12-

4. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



I

where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;


R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxy carbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

X-12591

-13-

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;


R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

-14-




R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxy carbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

X-12591

-15-

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

- a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and
- b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

6. (Amended) The method of Claim 3 where the mammal is human.

7. (new) The method of Claim 4 where the mammal is human.

8. (new) The method of Claim 5 where the mammal is human.

9. (new) A method for the treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I of Claim 1, or a pharmaceutically acceptable acid addition salt thereof.

10. (new) The method of Claim 9 where the mammal is human.


11. (new) A compound of Claim 1 where A is attached at the 7-position of the benzofuran nucleus.
12. (new) A compound according to Claim 11 where Q is hydrogen.
13. (new) A compound according to Claim 12 where R⁶ is C₁-C₄ alkyl and R⁵, R^{5'}, R⁷ and R^{7'} are each hydrogen.
14. (new) A compound according to Claim 13 where R^{6'} is hydrogen, and R⁶ and the benzofuran core are in the cis configuration with regard to each other.
15. (new) A compound according to Claim 13 where R⁶ is methyl.
16. (new) A compound according to Claim 13 where R^{6'} is methyl.
17. (new) A compound according to Claim 11 where one of R^{5'} and Q, or R^{6'} and Q, taken together with the carbon atoms to which they are attached form a double bond.
18. (new) A compound according to Claim 17 where of R^{5'} and Q, taken together with the carbon atoms to which they are attached form a double bond, R⁶ is C₁-C₄ alkyl, and R^{6'} is methyl.
19. (new) A compound according to Claim 18 which is 3,3-dimethyl-4-(6-fluorobenzothien-7-yl)-1,2,3,6-tetrahydropyridine.

-1-

SEROTONERGIC BENZOTHIOPHENES

The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) has a rich pharmacology arising from a heterogeneous population of at least seven receptor classes. The serotonin 5-HT₂ class is further subdivided into at least three subtypes, designated 5-HT_{2a}, 5-HT_{2b}, and 5-HT_{2c}. The 5-HT_{2c} receptor has been isolated and characterized (Julius, *et al.*, U.S. Patent No. 4,985,352), and transgenic mice lacking the 5-HT_{2c} receptor have been reported to exhibit seizures and an eating disorder resulting in increased consumption of food (Julius, *et al.*, U.S. Patent No. 5,698,766). Compounds selective for the 5-HT_{2c} receptor would provide useful therapies for the treatment of seizure and eating disorders without the side effects associated with current therapies. The present invention provides new benzothiophenes that are useful 5-HT_{2c} receptor agonists.

The present invention provides benzothiophenes of Formula I:



I

where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent

-3-

b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

This invention also provides a pharmaceutical formulation which comprises, in association with a pharmaceutically acceptable carrier, diluent or excipient, a compound of Formula I.

The present invention provides a method for increasing activation of the 5-HT_{2C} receptor in mammals comprising administering to a mammal in need of such activation a pharmaceutically effective amount of a compound of Formula I

The present invention also provides a method for treating obesity in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of Formula I.

A further embodiment of this invention is a method for increasing activation of the 5-HT_{2C} receptor for treating a variety of disorders that have been linked to decreased neurotransmission of serotonin in mammals. These disorders include depression, obesity, bulimia, premenstrual syndrome or late luteal phase syndrome, alcoholism, tobacco abuse, panic disorder, anxiety, post-traumatic syndrome, memory loss, dementia of aging, social phobia, attention deficit hyperactivity disorder, disruptive behavior disorders, impulse control disorders, borderline personality disorder, obsessive compulsive disorder, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, anxiety, seizure disorders, and mutism. Any of these methods employ a compound of Formula I.

This invention also provides the use of a compound of Formula I for the manufacture of a medicament for the treatment of obesity. Additionally, this invention provides

-4-

a pharmaceutical formulation adapted for the treatment of obesity containing a compound of Formula I. Furthermore, this invention includes a method for the treatment of obesity which comprises administering an effective amount of
5 a compound of Formula I.

The general chemical terms used in the formulae above have their usual meanings. For example, the term "alkyl" includes such groups as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and the like. The
10 term "alkoxy" includes methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term "acyl" includes such groups as formyl, acetyl, propionyl, butyryl, 2-methylpropionyl, and the like. The term "halo" includes fluoro, chloro, bromo and iodo.

15 The term "C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy" means a branched or linear alkyl group substituted in the carbon chain with one or two substituents independently selected from hydroxy or C₁-C₄ alkoxy.

20 The term "C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl" means a branched or linear alkyl group which may be substituted in the carbon chain with a phenyl or pyridinyl ring.



25 Since the compounds of this invention are amines, they are basic in nature and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are
30 typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature.

-5-

Acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen-phosphate, dihydrogenphosphate, metaphosphate, pyro-phosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid and fumaric acid.





The skilled artisan will appreciate that substituents on moiety "A" of certain compounds of the present invention give rise to cis- and trans-isomers. An example of this isomeric relationship is illustrated by the following benzothienylpiperidines:

-6-



The compounds of the invention may exist as a mixture of cis- and trans-isomers or as the individual isomers. It is preferred that the compounds exist as the individual isomers. Compounds in the cis- configuration are especially preferred.


The skilled artisan will also appreciate that the compounds of the present invention have at least one chiral carbon, and may therefore exist as a racemate, as individual enantiomers or diastereomers, and as mixtures of individual enantiomers or diastereomers. Individual enantiomers of compounds of the invention are illustrated by the following structures where R^6 or R^7 are other than hydrogen:



15

-7-

Individual diastereomers are illustrated by the following structures:



The enantiomers and diastereomers illustrated above are representative of other enantiomers and diastereomers created by other combinations of certain non-hydrogen substituents on the compounds of the invention, and are not intended to limit the scope of the present invention in any way. Furthermore, the skilled artisan will appreciate that certain substituents on the benzothiophenyl ring of the compounds of the invention introduce additional asymmetric centers into the molecule, creating additional optical isomers as described above.

While it is a preferred embodiment of the invention that the compounds of the invention exist, are formulated, and are used as single enantiomers or diastereomers, the present invention also contemplates the compounds of the invention existing in racemic form and as mixtures of the individual enantiomers and diastereomers. The methods and formulations of the invention also contemplate the use and formulation of the compounds of the invention in their racemic form and as mixtures of the individual enantiomers and diastereomers.

The individual enantiomers and diastereomers may be prepared by chiral chromatography of the racemic or enantiomerically or diastereomerically enriched free amine,

-8-

or fractional crystallization of salts prepared from racemic or enantiomerically or diastereomerically enriched free amine and a chiral acid. Alternatively, the free amine may be reacted with a chiral auxiliary and the enantiomers or diastereomers separated by chromatography followed by removal of the chiral auxiliary to regenerate the free amine. Furthermore, separation of enantiomers or diastereomers may be performed at any convenient point in the synthesis of the compounds of the invention. The compounds of the invention may also be prepared by the use of chiral syntheses. A particularly useful method for the separation of enantiomers or diastereomers is the "Dutch Resolution" described in EP 0 838 448 A1 (See also: T. Vries, et al., Angew. Chem. Int. Ed., **37**, 2349-2354 (1998); and B. Broxterman, et al., Chim. Oggi., **16**, 34-37 (1998)). Especially useful salts for resolution include 3-bromo-camphor-8-sulfonic acid, mandelic acid, dibenzoyltartaric acid, di-(p-methylbenzoyl)tartaric acid, and di-(p-methoxybenzoyl)tartaric acid.

While all of the compounds of Formula I are useful 5-HT_{2C} agonists, certain classes of the compounds are preferred. The following paragraphs describe such preferred classes:

aa) A is attached at the 7-position of the benzothiophene ring;

ab) n is 0 or 1;

ac) n is 1;

ad) Q is hydrogen;

ae) Q and R^{5'}, taken together with the carbon atoms to which they are attached, form a double bond;

af) Q and R^{6'}, taken together with the carbon atoms to which they are attached, form a double bond;

ag) R is hydrogen;

ah) R is halo;

-9-

- ai) R is C₁-C₆ alkyl;
- aj) R¹ is hydrogen;
- ak) R¹ is halo;
- al) R¹ is trifluoromethyl;
- 5 am) R¹ is C₁-C₆ alkyl;
- an) R² is hydrogen;
- ao) R² is halo;
- ap) R² is fluoro;
- aq) R² is trifluoromethyl;
- 10 ar) R³ is hydrogen;
- as) R³ is halo;
- at) R³ is fluoro;
- au) R³ is trifluoromethyl;
- av) R⁴ is hydrogen;
- 15 aw) R⁴ is halo;
- ax) R⁴ is fluoro;
- ay) R⁴ is trifluoromethyl;
- az) R⁵ is hydrogen;
- ba) R⁵ is C₁-C₄ alkyl;
- 20 bb) R⁵ is methyl;
- bc) R^{5'} is hydrogen;
- bd) R^{5'} is methyl;
- be) R⁶ is hydrogen;
- bf) R⁶ is C₁-C₄ alkyl;
- 25 bg) R⁶ is methyl;
- bh) R^{6'} is hydrogen;
- bi) R^{6'} is methyl;
- bj) R⁷ is hydrogen;
- bk) R⁷ is C₁-C₄ alkyl;
- 30 bl) R⁷ is methyl;
- bm) R^{7'} is hydrogen;
- bn) R^{7'} is methyl;
- bo) The compound is a free base;

-10-

- bp) The compound is a salt;
- bq) The compound is the hydrochloride salt;
- br) The compound is the fumarate salt;
- bs) The compound is a racemate;
- 5 bt) The compound is a single enantiomer;
- bu) The compound is a single diastereomer;
- bv) A is attached at the 7-position of the benzothienyl moiety and only one of R², R³, or R⁴ is hydrogen;
- bw) A is attached at the 7-position of the benzothienyl
10 moiety and any two of R², R³, or R⁴ is hydrogen;
- bx) A is attached at the 7-position of the benzothienyl moiety and all three of R², R³, and R⁴ are other than hydrogen;
- by) One of R⁵, R⁶, and R⁷ is other than hydrogen;
- 15 bz) Two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} are other than hydrogen;
- ca) n is 1 and A is monosubstituted in the three position;
- cd) n is 1 and A is substituted in both the two and
20 three positions.

It will be understood that the above classes may be combined to form additional preferred classes.

The present invention also provides a method for
25 increasing activation of the 5-HT_{2C} receptor in mammals by administering to a mammal in need of such activation a pharmaceutically effective amount of a compound of Formula I. The preferred mammal is human.


The compounds of the invention may be prepared
30 beginning with an appropriately substituted benzothiophene and a suitable ketone as illustrated in the following scheme, where X is bromo or iodo, Pg is a nitrogen

-11-

protecting group; and the variables n , R , R^1 , R^2 , R^3 , R^4 , R^5 , R^5' , R^6 , R^6' , R^7 , and R^7' are as previously defined:

Synthetic Scheme I

5



-12-

An appropriately substituted bromo- or iodobenzothiophene (a) in an appropriate solvent, typically tetrahydrofuran or diethyl ether, is treated with magnesium metal to prepare the corresponding Grignard reagent (b). Alternatively, a solution of the bromo- or iodobenzothiophene in a suitable solvent, typically diethyl ether or tetrahydrofuran, is treated with an alkylolithium, typically tert-butyllithium, to prepare the corresponding organolithium reagent (b). Either of these reagents is then reacted with an appropriately substituted, nitrogen protected, pyrrolidinone (n=0), piperidinone (n=1), or homopiperidinone (n=2) (c) to prepare the benzyl alcohol (d). Nitrogen protecting groups useful for this reaction are well known to the skilled artisan. A summary of such groups may be found in Greene's Protective Groups in Organic Synthesis, Second Edition, Wiley Interscience. Particularly useful protecting groups include benzyl and tert-butoxycarbonyl.

The skilled artisan will appreciate that benzothiophenes where R is hydrogen may be too acidic to tolerate the reaction conditions previously described. The 2-position of these benzothiophenes may be protected by treatment with an alkylolithium, typically n-butyllithium, at low temperature and then quenching the resulting anion solution with trimethylsilyl chloride. The resulting 2-trimethylsilylbenzothiophene may be deprotected by treatment with acid at any convenient point in the synthesis of the compounds of the present invention.

The benzyl alcohol (d) is dehydrated by treatment with an acid, typically p-toluenesulfonic acid, methanesulfonic acid, hydrochloric acid or hydrobromic acid, to provide a mixture of alkenes. When Pg is a moiety stable to acidic dehydration conditions, exemplified by compounds where Pg is benzyl, the alkenes of formula (e) and (f) are prepared. When Pg is


-13-

labile to acidic conditions, exemplified by compounds where Pg is tert-butoxycarbonyl, the compounds of formula (g) and (h) are prepared directly. The alkenes may be conveniently hydrogenated over a catalyst, preferably a palladium catalyst, to provide the corresponding piperidines. Either of these mixtures of alkenes may be separated into their individual isomers by chromatography or fractional crystallization. The compounds may then be nitrogen deprotected, if necessary, to provide compounds of the present invention.

10 An alternative to the acidic dehydration of the benzyl alcohol (d) followed by hydrogenation sequence is a tin mediated deoxygenation. This deoxygenation is accomplished by first converting the benzylic alcohol to the corresponding oxalate ester by treatment with methyl chlorooxalate under
15 standard acylation conditions. The resulting derivative is treated with tri(n-butyl)tin hydride in the presence of 2,2'-azobisisobutyronitrile to provide the compound of formula (j). This compound is then nitrogen deprotected to provide compounds of the present invention.

20 An alternative to the anion based coupling described above is the palladium catalyzed coupling described in the following scheme, where the variables are as previously described.

-14-

Synthetic Scheme II

An appropriately substituted bromobenzothiophene and the requisite N- protected dihydropyrrole ($n=0$), tetrahydropyri-
 5 dine ($n=1$) or didehydrohomopiperidine ($n=2$) in an appropriate solvent, typically dimethylformamide, is heated with a source of palladium, such as palladium acetate, an appropriate phosphine, such as tri(fur-2-yl)phosphine, an appropriate amine, such as diisopropylethylamine, and lithium chloride.
 10 The product of this coupling reaction is then nitrogen deprotected to provide compounds of the present invention.

Alternatively, the palladium-mediated coupling may be performed on an appropriately substituted benzothienylboronic acid derivative and an appropriate enoltriflate derivative of
 15 the corresponding pyrrolidinone, piperidinone, or homopiperidinone. These coupling partners may be prepared from the corresponding bromobenzothiophenes and ketones respectively by procedures well known in the art. This type of palladium coupling reaction is well known in the art (See:


-15-

N. Miyaoura et al., Journal of Organic Chemistry, **51**, 5467-5471 (1986); Y. Hoshino, et al., Bull. Chim. Soc. Jap., **61**, 3008-3010 (1988); N. Miyaoura et al., Journal of the American Chemical Society, **111**, 314-321 (1989); W. J. Thompson, et al.,
5 Journal of Organic Chemistry, **53**, 2052-2055 (1988); and T. I. Wallow and B. M. Novack, Journal of Organic Chemistry, **59**, 5034-5037 (1994)).

The skilled artisan will appreciate that the conditions for any of the nitrogen deprotection steps described above
10 depend upon the nature of the nitrogen protecting group. For example, the benzyl group may be removed by treatment with 1-chloroethyl chloroformate or by catalytic hydrogenation. The tert-butoxycarbonyl group may be removed by treatment with acid, for example, trifluoroacetic acid or hydrogen chloride.

15 The benzothiophenes required for the preparation of the novel compounds useful for the method of the present invention are either commercially available or may be prepared by methods well known to the skilled artisan. For example, Method (a) of Synthetic Scheme III is that of Beck et al.
20 (Journal of Organic Chemistry, **37**(21), 3224 (1972)); and Method (b) of is that of Bridges et al., Tetrahedron Letters, **33**(49), 7499 (1992). R², R³ and R⁴ are as previously defined.

-16-

Synthetic Scheme III

5

The three methods described in Synthetic Scheme IV provide the requisite benzothiophenes from three different structural classes of starting materials. The selection of a particular method is dependent upon the availability of starting materials and the stability of the substituents to the particular reaction conditions.

Method (a) of Synthetic Scheme III takes advantage of the relative acidity of aromatic protons adjacent to a carbon bearing a fluorine atom. Treatment of an appropriate

-17-

fluorobenzene with a suitable base followed by addition of dimethylformamide provides, after an aqueous acid workup, the corresponding fluorobenzaldehyde. Suitable bases for this transformation include alkylolithiums such as n-butyllithium or
5 sec-butyllithium, and lithium amides such as lithium 2,2,6,6-tetramethylpiperidide or lithium diisopropylamide. The resulting fluorobenzaldehyde is treated with the anion of methyl thioglycollate. This anion may first be formed by treatment of a solution of methyl thioglycollate in dimethyl-
10 sulfoxide with a metal hydride, preferably sodium hydride, and then adding the fluorobenzaldehyde. The exothermic reaction provides the corresponding methyl benzothiophene-2-carboxylate. Alternatively, the fluorobenzaldehyde, methyl thioglycollate and a suitable tertiary amine, preferably
15 triethylamine, are heated together in dimethylsulfoxide to prepare the corresponding methyl benzothiophene-2-carboxylate.

An alternate route to the same methyl benzothiophene-2-carboxylate is illustrated by method (b) of Synthetic Scheme III. This method exploits the facility with which an aromatic
20 nitro group can undergo nucleophilic displacement. A suitable o-nitrobenzaldehyde is treated with an equimolar amount of methyl thioglycollate and potassium carbonate in dimethylformamide.

The methyl benzothiophene-2-carboxylates prepared by
25 either of these two methods is converted to the required benzothiophene by standard ester hydrolysis/decarboxylation steps. A solution of the appropriate ester in a lower alkanol, typically methanol or ethanol, is treated with a small excess of sodium or potassium hydroxide. Once the
30 hydrolysis is complete, volatiles are removed under reduced pressure. The residue is taken up in quinoline and to this mixture is added elemental copper. The reaction mixture is then heated to about 200°C until the decarboxylation is

-18-

complete. The desired product is isolated by normal extractive techniques and may be purified by chromatography or crystallization as appropriate prior to subsequent use.

Method (c) provides the requisite benzothiophenes from
 5 appropriately substituted thiophenols, including aminothiophenols. A solution of the thiophenol in an appropriate solvent, such as acetone, tetrahydrofuran or diethyl ether, is treated with potassium carbonate followed by bromoacetaldehyde diethyl acetal. The resulting mixture is stirred at about
 10 ambient temperature for from 1 hour to about 48 hours until the reaction is complete. The reaction mixture is then filtered and the filtrate concentrated under reduced pressure. The residue is subjected to an extractive workup and the product may be used directly in the subsequent step or
 15 purified by chromatography or crystallization if desired. This material is then dissolved in an appropriate solvent, typically a halobenzene such as chlorobenzene, and is treated with a suitable acid, typically polyphosphoric acid. The reaction is heated to reflux until the cyclization is
 20 complete. The desired benzothiophene may be isolated by normal extractive workups. In those cases where substituents are such that isomeric benzothiophenes may result from the cyclization, the isomers may be separated by chromatographic or crystallization techniques at this or any subsequent
 25 convenient point in the synthetic pathway to compounds of the present invention.

The skilled artisan will appreciate that the requisite thiophenols are either commercially available or may be prepared by methods well known to those skilled in the art.

30 Those compounds of the present invention where the benzothiophene ring is substituted with hydroxy are easily prepared by trimethylsilyl iodide cleavage of the corresponding alkoxy compound, or catalytic O-debenzylation of

-19-

the corresponding benzyloxy compound. This hydrogenolysis may be performed by dissolution of an appropriate substrate in a lower alkanol, such as methanol or ethanol, tetrahydrofuran or a mixed solvent system of tetrahydrofuran and ethyl acetate.

5 The hydrogenation may be performed at an initial hydrogen pressure of 20-80 p.s.i., preferably from 50-60 p.s.i., at 0-60°C, preferably at ambient temperature to 40°C, for 1 hour to 3 days. Additional charges of hydrogen may be required to drive the reaction to completion depending on the specific
10 substrate. Compounds prepared in this manner are isolated by removal of the catalyst by filtration followed by concentration of the reaction solvent under reduced pressure. The recovered product may be purified by chromatography or recrystallization from a suitable solvent if necessary.


15 The skilled artisan will appreciate that benzothio-phenes substituted in the 2- and/or 3-position may be prepared by modification of the chemistry described in Synthetic Scheme III. For example, a thiophenol may be alkylated with a suitable haloketone and then cyclized to
20 provide a substituted benzothiophene. Alternatively, the benzothienyl moiety may be substituted in the 2- or 3-position at any convenient point in the synthesis of the compounds of the present invention by methods known to those skilled in the art.

25 The requisite pyrrolidinones (n=0) and piperidinones (n=1) are either commercially available or may be prepared by methods well known in the art. The requisite homopiperidinones (n=2) may be prepared from appropriately substituted piperidinones. One such approach is a
30 modification of a synthesis described by Roglans, et al., Synthetic Communications, **22**(9), 1249-1258 (1992). Procedures for the preparation of pyrrolidinones and

-20-

homopiperidinones are described in the following scheme where the variables are as previously described.

Synthetic Scheme IV



5

The requisite pyrrolidinones ($n = 0$) may be prepared by reacting an ester, for example the ethyl ester, of an α -amino acid with methyl chloroformate. The resulting carbamate is treated with base and then with an appropriately substituted acrylic acid ester. The resulting α -keto ester is treated with base and an appropriate alkylating agent, such as an alkyl halide, followed by

10

-21-

decarboxylation and deprotection in the presence of aqueous acid to provide the desired compound.

The requisite homopiperidinones may be prepared from the corresponding piperidine via standard ring expansion protocols employing ethyl diazoacetate and an appropriate Lewis acid, such as boron trifluoride. The resulting α -keto ester is treated with base and an appropriate alkylating agent, such as an alkyl halide, followed by decarboxylation and deprotection in the presence of aqueous acid to provide the desired compound. The skilled artisan will appreciate that subsequent transformations are possible, if necessary or desired, to prepare more highly substituted compounds.

The skilled artisan will appreciate that not all substituents are compatible with the reaction conditions employed to prepare the compounds of the invention. Those substituents incompatible with these conditions may be introduced at a more convenient point in the synthesis, or may be prepared by functional group transformations well known to one of ordinary skill in the art. Furthermore, many of the compounds of the present invention, while useful 5-HT_{2C} agonists in their own right, are useful intermediates to prepare other compounds of the invention. Those compounds of the invention bearing an ester functionality, for example, may be hydrolyzed under standard conditions to provide the corresponding carboxylic acids. These acids may then be reacted with amines under standard peptide coupling conditions to provide the corresponding amides. Alternatively, the esters may be reduced to provide the corresponding alcohols. Furthermore, alkoxy groups may be cleaved to provide the corresponding phenols, and primary amines may be diazotized and displaced to provide the corresponding halogenated compounds.

-22-

The following Preparations and Examples are illustrative of methods useful for the synthesis of the compounds of the present invention.

The 2-trimethylsilylbenzothiophenes necessary for the preparation of the compounds of the present invention may be prepared essentially as described in Preparation I.

Preparation I

2-trimethylsilyl-6-fluorobenzothiophene

10 A solution of 13.6 gm (89.2 mMol) 6-fluorobenzothiophene in 59 mL tetrahydrofuran was cooled to -78°C. To this solution were added 66.9 mL (107.1 mMol) n-butyllithium (1.6 M in hexane) at a rate to maintain the reaction mixture at or below -65°C. The reaction mixture was stirred for one
15 hour while allowing to warm to -60°C. At this point 13.6 mL (107.1 mMol) trimethylsilyl chloride were added over 10 minutes. The reaction mixture was allowed to warm to room temperature. After about 1 hour, the reaction mixture was quenched by the addition of 75 mL saturated aqueous ammonium
20 chloride and 25 mL water. The resulting mixture was diluted with 100 mL hexane and the phases separated. The aqueous phase was extracted 2 x 100 mL hexane. The organic phases were combined, washed with saturated aqueous sodium chloride, dried over sodium sulfate and concentrated under
25 reduced pressure to provide 19.4 gm (97%) of the title compound as a crystalline solid.
m.p. = 40-42°C

30 The thiophenols necessary for the preparation of the compounds of the present invention may be prepared from the corresponding phenols essentially by the procedure described in Preparation II.

-23-

Preparation II

2-bromo-5-fluorothiophenol

A solution of 12.9 gm (105 mMol) N,N-dimethylthio-
 carbamoyl chloride in dimethylformamide was added to a
 5 mixture of 10 gm (52 mMol) 2-bromo-5-fluorophenol, and 11.7
 gm (105 mMol) 1,4-diazabicyclo[2,2,2]octane in 100 mL
 dimethylformamide. The reaction mixture was stirred at room
 temperature for 2 hours. The mixture was then diluted with
 water and the aqueous phase washed well with ethyl acetate.
 10 The combined organic phases were washed sequentially with 1N
 hydrochloric acid, water, and saturated aqueous sodium
 chloride, dried over sodium sulfate and concentrated under
 reduced pressure.

This residue was dissolved in diphenyl ether and heated
 15 at 230-240°C for about 4 hours. The reaction mixture was
 cooled to room temperature and was then poured over a silica
 gel column. The column was eluted first with hexane to
 remove the diphenyl ether, and then with a gradient of
 hexane containing 5-20% ethyl acetate. Fractions containing
 20 the desired compound were combined and concentrated under
 reduced pressure to provide 11 gm of the desired compound.

A mixture of 2.5 gm (9.0 mMol) of the resulting
 carbamate and 1.5 gm (27 mMol) potassium hydroxide in 50 mL
 methanol was heated at reflux for 1.5 hours. The reaction
 25 mixture was then diluted with water and extracted well with
 diethyl ether. The aqueous phase was then made acidic with
 hydrochloric acid and extracted well with ethyl acetate.
 These organic phases were combined, washed with saturated
 aqueous sodium chloride, dried over sodium sulfate and
 30 concentrated under reduced pressure. The residue was
 purified by silica gel chromatography to provide 1.7 gm
 (91%) of the title compound.

-24-

Preparation III

4-fluoro-7-bromobenzothiophene

2-(2-bromo-5-fluorophenylthio)acetaldehyde diethylacetal

A mixture of 1.9 gm (9.66 mMol) 2-bromoacetaldehyde
 5 diethylacetal and 2.6 gm (19.3 mMol) potassium carbonate in
 100 mL dimethylformamide was deoxygenated by bubbling in
 nitrogen for 30 minutes. To this mixture were added 2.0 gm
 (9.66 mMol) 2-bromo-5-fluorothiophenol and the reaction
 mixture was stirred at room temperature for about 64 hours.
 10 The reaction mixture was then diluted with water and
 extracted well with ethyl acetate. The organic extracts
 were combined, washed well with water, dried over sodium
 sulfate, and concentrated under reduced pressure to provide
 2.95 gm (95%) of the desired compound.

15

Cyclization

A mixture of 20 gm polyphosphoric acid in 300 mL
 chlorobenzene was heated at reflux. To this mixture was
 added a solution of 5 gm 2-(2-bromo-5-fluorophenylthio)acet-
 20 aldehyde diethylacetal in 100 mL chlorobenzene dropwise.
 The reaction mixture was heated at reflux for about 16
 hours. The reaction mixture was cooled to room temperature
 and the chlorobenzene decanted from the polyphosphoric acid.
 The chlorobenzene was concentrated under reduced pressure
 25 and the residue was dissolved in ethyl acetate. This
 solution was washed sequentially with 0.5 M sodium hydroxide
 and saturated aqueous sodium chloride, dried over sodium
 sulfate and concentrated under reduced pressure. The
 residue was subjected to silica gel chromatography, eluting
 30 with 5% ethyl acetate in hexane. Fractions containing
 product were combined and concentrated under reduced
 pressure to provide 2.4 gm (76%) of the title compound as a
 pale yellow solid.

25 Beginning with 36.3 gm (132 mMol) 2-(3-bromophenyl-
thio)acetaldehyde ethylene glycol acetal, 15.6 gm (57%) of
the title mixture were prepared essentially as described in
Preparation III.

A solution of 26 gm (101 mMol) methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate and 11.9 gm (106 mMol) potassium tert-butoxide in 300 mL tert-butanol was heated to 70°C under nitrogen. To this solution were then added 23.6 gm (152 mMol) iodoethane over 20 minutes, and the reaction mixture was heated at reflux for about 16 hours. The reaction mixture was then cooled to room temperature and was diluted with diethyl ether. The organics were washed with water, dried over magnesium sulfate, and concentrated under reduced pressure to provide 28.7 gm (99%) of the desired compound as a yellow oil.

-27-

3-ethyl-4-oxopiperidine hydrochloride

A mixture of 28.2 gm (98.8 mMol) methyl 1-tert-butoxycarbonyl-4-oxo-3-ethyl-3-piperidinecarboxylate and 6N hydrochloric acid was heated at reflux for about 16 hours.

- 5 The reaction mixture was concentrated under reduced pressure and the residue dissolved in ethanol. This solution was concentrated under reduced pressure to azeotropically remove water. This procedure was repeated twice to provide 7.0 gm (55%) of the desired compound.

10

Benzylation

- A mixture of 7.0 gm (54.8 mMol) 3-ethyl-4-oxopiperidine and 22.7 gm (164.4 mMol) potassium carbonate in 100 mL tetrahydrofuran was cooled to 0°C with vigorous stirring. A
15 solution of 9.2 gm (53.7 mMol) benzyl bromide in 20 mL tetrahydrofuran was added dropwise over 20 minutes. The reaction mixture was then allowed to warm gradually to room temperature. After about 16 hours the reaction mixture was diluted with water and was extracted with 2 x 250 mL
20 dichloromethane. The organic phases were combined, dried over magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with a gradient of hexane containing from 5-15% ethyl acetate. Fractions containing product were
25 combined and concentrated under reduced pressure to provide 9.4 gm (79%) of the title compound as a light yellow oil.

Preparation VII

1-benzyl-3,3-dimethyl-4-oxopiperidine

- 30 Methyl N-[benzyl] 3-aminopropionate

A solution of 55 mL (0.50 mole) benzylamine in 250 mL methanol was cooled in an ice bath. A solution of 54 mL (0.60 mole) methyl acrylate in 50 mL methanol was added

-28-

dropwise over 30 minutes. The reaction mixture was then allowed to warm gradually to room temperature. After about 96 hours the reaction mixture was concentrated under reduced pressure and the residue vacuum distilled to provide 74.6 gm
5 (77%) of the desired compound in two fractions.

Methyl N-[benzyl]-N-[methyl malonoyl] 3-aminopropionate

144 mL (1.25 mole) dimethyl malonate was heated at from 165 - 175°C. To this heated substrate was added 48.6 gm
10 (0.25 mole) methyl N-[benzyl] 3-aminopropionate dropwise. Methanol was distilled off as the reaction proceeded. After 8.0 mL of methanol was recovered, the temperature of the reaction mixture was increased to 180 - 185°C. After 1 hour at this temperature, an additional 1.5 mL of methanol had
15 been recovered. The reaction mixture was then cooled to room temperature and the excess dimethyl malonate was removed by vacuum distillation. The residue was subjected to silica gel chromatography, eluting with a gradient of hexane containing from 0-50% ethyl acetate. Fractions
20 containing the desired product were combined and concentrated under reduced pressure to provide 55.7 gm (76%).

Methyl 1-benzyl-2,4-dioxo-3-piperidinecarboxylate

25 A mixture of 130 gm (0.94 mole) potassium carbonate and 5 gm (18.9 mMol) 18-crown-6 in 500 mL toluene was heated at reflux. A solution of 55 gm (188 mMol) methyl N-[benzyl]-N-[methyl malonoyl] 3-aminopropionate in 150 mL toluene was added dropwise over 30 minutes. After 6 hours the reaction
30 mixture was cooled to room temperature and then diluted with 1L water. The toluene phase was diluted with 150 mL ethyl acetate and the phases separated. The organic phase was extracted with 2 x 250 mL water. The combined aqueous

phases were cooled in an ice bath as 6N hydrochloric acid was added until pH<1. The aqueous phase was then extracted with 3 x 300 mL dichloromethane. The combined dichloromethane extracts were dried over magnesium sulfate and concentrated under reduced pressure to provide 23.4 gm (48%) of the desired compound. The toluene/ethyl acetate extract was washed with saturated aqueous sodium chloride and then concentrated under reduced pressure to provide 26.1 gm (47%) unreacted methyl N-[benzyl]-N-[methyl malonoyl] 3-aminopropionate.

1-benzyl-2,4-dioxopiperidine

A mixture of 23.4 gm (89.7 mMol) methyl 1-benzyl-2,4-dioxo-3-piperidinecarboxylate in 200 mL 10% aqueous oxalic acid was stirred at reflux for 15 hours. The reaction mixture was cooled to room temperature and the solution extracted with 3 x 200 mL dichloromethane. The organic phases were combined, dried over magnesium sulfate, and concentrated under reduced pressure to provide 4.99 gm (27%) of the desired compound.

1-benzyl-2,4-dioxo-3,3-dimethylpiperidine

A mixture of 1.44 gm (7.1 mMol) 1-benzyl-2,4-dioxopiperidine, 4.0 gm (28.9 mMol) potassium carbonate, and 1.5 mL (24.1 mMol) iodomethane in 14 mL dimethylsulfoxide was stirred for 24 hours. The reaction mixture was diluted with ethyl acetate and water. The phases were separated and the organic phases was washed sequentially with water and saturated aqueous sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with hexane containing 35% ethyl acetate. Fractions containing product were combined and concentrated under

-30-

reduced pressure to provide 0.61 gm (37%) of the desired compound.

1-benzyl-3,3-dimethyl-4-hydroxypiperidine

5 A solution of 0.30 gm (1.3 mMol) 1-benzyl-2,4-dioxo-3,3-dimethylpiperidine in 5 mL tetrahydrofuran was stirred at room temperature as 2 mL (2 mMol) lithium aluminum hydride (2M in tetrahydrofuran) was added dropwise. The reaction mixture was then heated to reflux for 3 hours. The
10 reaction mixture was then allowed to cool to room temperature. After stirring at room temperature for about 16 hours, the reaction mixture was cooled in an ice bath and treated sequentially with 0.5 mL water, 0.5 mL 5N sodium hydroxide, and 0.5 mL water with vigorous stirring. The
15 resulting slurry was diluted with dichloromethane and anhydrous sodium sulfate was added. The slurry was filtered and the filter cake washed with dichloromethane. The combined filtrates were concentrated under reduced pressure and the residue subjected to silica gel chromatography,
20 eluting with dichloromethane containing from 0-10% methanol containing 0.1% ammonium hydroxide. Fractions containing product were combined and concentrated under reduced pressure to provide 0.25 gm (88%) of the desired compound.

25 Oxidation

A solution of 0.40 mL (5.6 mMol) dimethylsulfoxide in 5 mL dichloromethane was cooled to -78°C. To this solution was added 0.35 mL (2.48 mMol) trifluoroacetic anhydride dropwise and the resulting solution stirred for 30 minutes.
30 A solution of 0.25 gm (1.14 mMol) 1-benzyl-3,3-dimethyl-4-hydroxypiperidine in 2 mL dichloromethane was added dropwise and the reaction mixture was stirred for 1 hour. To the solution was then added 1.0 mL (7.2 mMol) triethylamine and

-31-

the reaction mixture was warmed to 0°C. After stirring for 2 hours, the reaction mixture was poured into water and extracted with ethyl acetate. The organic extracts were combined, dried over sodium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with hexane containing from 0-20% ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure to provide 0.20 gm (79%) of the title compound.

10

Preparation VIII

Alternate Synthesis of 1-benzyl-3,3-dimethyl-4-oxopiperidine

Benzylamine (214 g, 2 mol) is combined with formaldehyde (37% in water, 375 g, 4.5 mol) in ethanol (1 L) with occasional cooling. This biphasic mixture is added over a period of 90 minutes to a refluxing solution of 2-methyl-3-butanone (182 g, 2.11 mol) in anhydrous ethanol (1L) and hydrochloric acid (209 g of 37% solution, 2.1 mol). The brownish solution is heated at reflux for an additional 18 hours. Then triethylamine (310 mL, 223.8 g, 2.21 mol) and formaldehyde (50 g, 36%, 0.6 mol) are added sequentially and the reaction mixture is heated at reflux for 24 hours. The reaction mixture is then cooled to 5°C and treated with potassium hydroxide (117.6 g, 2.1 mol, dissolved in 200 mL of water). The reaction mixture is then extracted with heptane (2 X 500 mL) and methyl tert-butyl ether (2 X 500 mL). The organic extracts is then combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to provide the title compound, (339.36 g after 18% by volume of the above combined organic extracts was removed prior to concentration). This material was purified by chromatography on silica gel (methylene chloride/ethanol, 100:1) to provide purified title compound.

-32-

^1H NMR (CDCl_3) δ 1.14 (s, 6H), 2.41 (s, 2H), 2.52 (t, 2H), 2.72 (t, 2H), 3.57 (s, 2H), 7.2-7.4 (m, 5H).

Preparation IX

5 Alternate Synthesis of 1-benzyl-3,3-dimethyl-4-oxopiperidine

In a 1 liter 3-necked flask equipped with mechanical stirring, addition funnel and a calcium chloride drying tube is added a 37% weight solution of formaldehyde (168.5 mL, 2.25 mole) dissolved in 500 mL of absolute ethanol. The

10 resulting solution is cooled in an ice-water bath to 10°C, and benzylamine (109 mL, 1mole) is added dropwise over a one hour period. In a separate 3 liter 3-necked flask equipped with mechanical stirring, addition funnel and two condensers is added 3-methyl-2-butanone (113 mL, 1.06mole) dissolved in

15 500ml of absolute ethanol and concentrated hydrogen chloride (92 mL, 1.11mole). The resulting solution is brought to reflux and the formaldehyde/benzylamine solution is added dropwise over a 2 hour period. This solution is refluxed overnight, and then cooled to ambient temperature.

20 Diisopropylethylamine (142.2 g, 1.1 mole) and formaldehyde (22.46 mL, 0.3mole) are added and the resulting solution is heated to reflux for six hours, and then cooled to ambient temperature. The solution is quenched with potassium hydroxide (61.6 g, 1.1 mole) in 200 mL of water, and then

25 extracted with 500 mL ethyl acetate three times. The organics are concentrated under vacuum to give 225 g of red oil. The crude oil is dissolved in 1 liter of methylene chloride. This solution is carefully poured over 1 kg of silica gel on a sintered glass filter. The silica gel is

30 washed with 4 L of methylene chloride. The methylene chloride is concentrated under vacuum to provide 142 g of a yellow oil which crystallizes in the freezer overnight. Yield=65.4%.

-33-

Preparation X

cis-1-benzyl-3,5-dimethyl-4-oxopiperidine

A solution of 45 mL (90.4 mMol) lithium diisopropyl-
5 amide (2.0 M in tetrahydrofuran) was cooled to -5°C. A
solution of 18.5 gm (75.4 mMol) 1-benzyl-3-methyl-4-
oxopiperidine N,N-dimethylhydrazone (prepared from 1-benzyl-
3-methyl-4-oxopiperidine and N,N-dimethylhydrazine) in 100
mL tetrahydrofuran was added dropwise over 40 minutes. The
10 reaction mixture was then cooled to -78°C and 5.16 mL (83
mMol) iodomethane were added dropwise. The reaction mixture
was stirred for about 16 hours, warming gradually to room
temperature. The resulting homogeneous yellow solution was
diluted with 300 mL dichloromethane and was washed first
15 with 100 mL water and then with saturated aqueous sodium
chloride. The organic phase was dried over magnesium
sulfate and then concentrated under reduced pressure.

This compound (8.5 gm) was dissolved in 200 mL 2.0 M
methanolic hydrogen chloride and the resulting mixture
20 heated at reflux for about 16 hours. The reaction mixture
was concentrated under reduced pressure and the residue
partitioned between 80 mL 5N sodium hydroxide and 200 mL
ethyl acetate. The aqueous phase was extracted 3 x 400 mL
ethyl acetate. The organic phases were combined, dried over
25 magnesium sulfate, and concentrated under reduced pressure.
The residue was subjected to silica gel chromatography,
eluting with a gradient of hexane containing from 0-20%
ethyl acetate. Fractions containing the desired compound
were combined and concentrated under reduced pressure to
30 provide 5.2 gm of the title compound.
Ion Spray MS: m/e = 218 (M+1)

A mixture of 5.0 gm (23 mMol) 1-benzyl-3,3-dimethyl-4-oxopiperidine, 2.5 gm 5% palladium on carbon, 5.0 gm (23 mMol) di(tert-butyl) dicarbonate in 100 mL ethanol was
30 pressurized to 50 p.s.i. with hydrogen and warmed to 50°C. After 18 hours the reaction mixture was filtered through a bed of celite and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel

-35-

chromatography, eluting with hexane containing 20% ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure to provide 2.9 gm (56%) of the title compound as a white solid.

5 $^1\text{H-NMR}(\text{CDCl}_3)$: δ 3.70 (br s 2H), 3.40 (br s 2H), 2.43 (t, 2H), 1.45 (s, 9H), 1.05 (s, 6H).

Preparation XIV

10 1-(tert-butoxycarbonyl)-2-methyl-4-trifluoromethanesulfonyl-oxy-1,2,3,6-tetrahydropyridine

A solution of 5 mL (49 mMol) 4-methoxypyridine in 200 mL tetrahydrofuran was cooled to -40°C , and then 6.9 mL (55 mMol) phenyl chloroformate were added dropwise. After stirring for 15 minutes, 20 mL (60 mMol) methyl magnesium chloride (3M in tetrahydrofuran) were added dropwise and the reaction mixture was allowed to warm to room temperature. After stirring for 30 minutes, the reaction mixture was cooled to -40°C and treated with 340 mMol potassium tert-butoxide. The reaction mixture was allowed to warm to room temperature. After stirring for 1 hour, the reaction mixture was cooled to -40°C and was treated with 200 mL saturated aqueous oxalic acid. The reaction was warmed to 20°C and allowed to stir for 1 hour. The mixture was extracted 2 x 200 mL diethyl ether. The combined organic phases were washed sequentially with 4 x 100 mL 0.5 N sodium hydroxide, 2 x 100 mL saturated aqueous sodium bicarbonate, 3 x 100 mL deionized water, and 100 mL saturated aqueous sodium chloride. The remaining organics were dried over magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with hexanes containing 40% ethyl acetate. Fractions containing product were combined and concentrated

-36-

under reduced pressure to provide 4.9 gm (47%) 1-(tert-butoxycarbonyl)-2-methyl-4-oxopiperidine.

EA: Calculated for: $C_{11}H_{17}NO_3$: C, 62.54; H, 8.11; N, 6.63.

Found: C, 62.78; H, 8.08; N, 6.76.

5 A solution of 1.65 gm (7.81 mmol) 1-(tert-butoxycarbonyl)-2-methyl-4-oxopiperidine in 20 mL tetrahydrofuran was cooled to -40°C and was then treated with 8.59 mL (8.59 mmol) lithium tri(sec-butyl)borohydride (1M in tetrahydrofuran). After stirring for 2 hours, the solution was
10 treated with 3.37 gm (8.59 mmol) 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine and the solution was allowed to warm to room temperature. After stirring for 1 hour, the reaction was diluted with 250 mL diethyl ether and filtered through celite. The celite pad was rinsed with 250
15 mL diethyl ether and the combined filtrates concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with hexanes containing from 0-9% ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure to provide
20 2.02 gm (75%) of the title compound.
ISMS: $m/e = 346$ (M+H)

Preparation XV

1-(tert-butoxycarbonyl)-2-methyl-4-oxopiperidine
25 A solution of 160.0 gm (733 mmol) di(tert-butyl)dicarbonate in 300 mL tetrahydrofuran was added dropwise to a solution of 100.0 gm (698 mmol) 1,4-dioxo-8-azaspiro-[4,5]decane in 800 mL tetrahydrofuran over 1 hour. The reaction mixture was stirred for 30 minutes after the
30 addition was complete and was then concentrated under reduced pressure. The residue was dissolved in 600 mL diethyl ether and was washed sequentially with 2 x 250 mL deionized water, 2 x 250 mL 5% aqueous sodium bicarbonate,

-37-

and 250 mL saturated aqueous sodium chloride. The organic phase was dried over potassium carbonate and concentrated under reduced pressure to provide 173.3 gm 8-(tert-butoxycarbonyl)-1,4-dioxo-8-azaspiro[4,5]decane.

5 A solution of 76.0 gm (312 mMol) 8-(tert-butoxycar-
bonyl)-1,4-dioxa-8-azaspiro[4,5]decane in 760 mL diethyl
ether was cooled to -78°C and was treated with freshly
distilled 49.5 mL (328 mMol) N,N,N',N'-tetramethylethylene-
diamine. One equivalent of a sec-butyllithium solution was
10 added dropwise over 1.5 hours, maintaining the temperature
of the reaction mixture below -70°C. After stirring for 4
hours at -78°C, 38.9 mL (625 mMol) iodomethane were added
over 10 minutes. The reaction mixture was stirred for 10
15 minutes and was then allowed to warm gradually to room
temperature. The reaction mixture was treated with 300 mL
deionized water and the phase were separated. The aqueous
phase was extracted with 300 mL diethyl ether. The organic
phases were combined, washed with 4 x 250 mL deionized
water, dried over potassium carbonate and concentrated under
20 reduced pressure. The residue was subjected to silica gel
chromatography, eluting with a gradient of hexanes
containing from 7-20% ethyl acetate. Fractions containing
product were combined and concentrated under reduced
pressure to provide 57.1 gm (71%) 7-methyl-8-(tert-
25 butoxycarbonyl)-1,4-dioxo-8-azaspiro[4,5]decane as a clear
oil. This material was cooled to 0-5°C and 279.2 mL
trifluoroacetic acid were added. After stirring for 10
minutes, 5.2 mL deionized water were added and the reaction
mixture was heated at reflux for 2.5 hours. The reaction
30 mixture was cooled to room temperature and concentrated
under reduced pressure. The residue was dissolved in 60 mL
ethyl acetate and 120 mL diethyl ether were added over 30
minutes with stirring. The suspension was held in a freezer

30 A mixture of 10.14 gm (46.66 mMol) 1-benzyl-3,3-dimethyl-4-oxopiperidine, 1.03 gm 10% palladium on carbon, and 11.09 gm (50.81 mMol) di-tert-butyl dicarbonate in 210 mL methanol was purged 3 times with nitrogen and 3 times with hydrogen. The mixture was placed under 50 psig of

-39-

hydrogen and was shaken at room temperature for 16 hours. The reaction mixture was filtered through a bed of celite and glass microfiber paper. The filtrate was concentrated under reduced pressure and the residue subjected to silica gel chromatography, eluting with hexanes containing 20% ethyl acetate. Fractions containing the product were combined and concentrated under reduced pressure to provide 9.38 gm (88.5%) of 1-(tert-butoxycarbonyl)-3,3-dimethyl-4-oxopiperidine.

10 A solution of 13.25 mL (26.5 mMol) lithium diisopropylamide (2M in tetrahydrofuran/heptane) was cooled to -78°C. A solution of 5.24 gm (23.05 mMol) of 1-(tert-butoxycarbonyl)-3,3-dimethyl-4-oxopiperidine in 40 mL tetrahydrofuran was added dropwise over 40 minutes, maintaining the reaction temperature below -71°C. After the addition was complete, the reaction mixture was stirred at -78°C for 90 minutes, and then a solution of 8.70 gm (24.35 mMol) N-phenyltrifluoromethanesulfonimide in 40 mL tetrahydrofuran was added over 10 minutes. The solution was allowed to warm to 0°C and was stirred for 90 minutes. The reaction mixture was concentrated under reduced pressure and the residue was subjected to neutral alumina chromatography, eluting with 5:1 hexanes:ethyl acetate. The solvent was removed under reduced pressure and the residue was subjected to silica gel chromatography, eluting with 4:1 hexanes:ethyl acetate. Fractions containing product were combined and concentrated under reduced pressure to provide 1.72 gm (75.2%) of the title compound as a clear, colorless oil.

Alternatively, the lithium diisopropylamide was generated in situ by reacting a solution of 0.86 μ L (6.14 mMol) diisopropylamine in 10 mL tetrahydrofuran with 2.2 mL (5.5 mMol) n-butyllithium (2.5 M in hexanes). After cooling this solution to -78°C, a solution of 1.076 gm (4.73 mMol)

-40-

1-(tert-butoxycarbonyl)-3,3-dimethyl-4-oxopiperidine in 12 mL tetrahydrofuran was added dropwise, maintaining the reaction temperature below -70°C. After the addition was complete, the reaction mixture was stirred at -78°C for 1
5 hour, and then a solution of 1.963 gm (5.00 mMol) 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine in 8 mL tetrahydrofuran was added over 5 minutes. The solution was allowed to warm to 0°C and was stirred for 90 minutes. The reaction mixture was concentrated under reduced pressure and
10 the residue was subjected to neutral alumina chromatography, eluting with 5:1 hexanes:ethyl acetate. The solvent was removed under reduced pressure to provide 1.566 gm (92.1%) of the title compound as a slightly yellow oil.

15

Preparation XVIII

(6-fluorobenzothien-7-yl)boronic acid

A solution of 4.25 mL (6.8 mMol) n-butyllithium (1.6 M in hexane) in 12 mL tetrahydrofuran was cooled to -78°C. To this solution was added a solution of 1.494 gm (6.46 mMol)
20 6-fluoro-7-bromobenzothiophene in 17 mL tetrahydrofuran over 35 minutes, maintaining the temperature less than -72°C. The reaction mixture was stirred for 40 minutes and then 810 µL (7.3 mMol) trimethylborate were added over 20 minutes. The reaction mixture was allowed to warm to 0°C, and was
25 held at this temperature for 1.5 hours. The reaction mixture was then treated with 7.5 mL 1N hydrochloric acid. The mixture was stirred for 15 minutes and the phases were separated. The aqueous phase was extracted well with diethyl ether. The organic phases were combined, dried over
30 sodium sulfate, and concentrated under reduced pressure. The residue was slurried in 15 mL hexanes for 1 hour, the solvent removed by decantation, and the solids dried under

-41-

reduced pressure to provide 1.234 gm of the title compound as a white solid.

Preparation XIX

5 6-fluoro-7-bromobenzothiophene

1-(methoxymethoxy)-3-fluorobenzene

A solution of 100 gm (0.892 mol) 3-fluorophenol in 800 mL dichloromethane was cooled to -10°C. To this solution were added 155 gm (1.20 mol) diisopropylethylamine dropwise
 10 over 15 minutes. Residual diisopropylethylamine in the addition funnel was rinsed into the reaction mixture with 100 mL dichloromethane. To the resulting solution were added 100 gm (1.24 mol) chloromethyl methyl ether over 5 minutes, resulting an exotherm from -10°C to 2°C. The
 15 reaction mixture was allowed to warm to room temperature. After 22 hours the reaction mixture was quenched with 500 mL water. The organic phase was washed with 500 mL 2M aqueous sodium bisulfate followed by 300 mL 1M sodium hydroxide. The remaining organics were dried over magnesium sulfate and
 20 concentrated under reduced pressure to provide 130 gm of a yellow oil. The oil was distilled (kugelrohr, 80°C, 0.1 torr) to provide 126 gm (91%) of the desired compound as a colorless oil.

25 1-(methoxymethoxy)-2-bromo-3-fluorobenzene

A solution of 270 mL (430 mMol) n-butyllithium (1.6 M in hexanes) in 800 mL tetrahydrofuran was cooled to -78°C. To this solution was added a solution of 60 gm (384 mMol) 1-(methoxymethoxy)-3-fluorobenzene in 100 mL tetrahydrofuran
 30 over 30 minutes. The resulting mixture was stirred for 1 hour and was then rapidly quenched with 67.5 gm (423 mMol) bromine. The reaction mixture was stirred for 30 minutes and was then partitioned by the addition of 500 mL methyl

-42-

tert-butyl ether and 300 mL saturated aqueous sodium thiosulfate. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. The residual oil was distilled (kugelrohr, 70-100°C, 0.1 torr) to provide 81.7 gm (91%) of the desired compound as a colorless oil.

2-bromo-3-fluorophenol

A mixture of 120 mL isopropanol, 200 mL 6M hydrochloric acid, and 81 gm (345 mMol) 1-(methoxymethoxy)-2-bromo-3-fluorophenol was stirred at room temperature. After 2.5 hours the reaction mixture was partitioned by the addition of 400 mL methyl tert-butyl ether and 120 mL 5N sodium hydroxide. The organic phase was washed with saturated aqueous sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residual oil was subjected to silica gel chromatography, eluting with dichloromethane. Fractions containing product were combined and concentrated under reduced pressure to provide 55.1 gm (84%) of the desired compound as a colorless oil.

O-(3-fluoro-2-bromophenyl)-N,N-diethylthiocarbamate

A solution of 54.7 gm (286 mMol) 2-bromo-3-fluorophenol and 19.3 gm (292 mMol) 85% sodium hydroxide in 200 mL water was cooled to 5°C and was then treated with a solution of 46.0 gm (372 mMol) N,N-diethylthiocarbonyl chloride in 150 mL tetrahydrofuran over 30 minutes. After 20 minutes the reaction mixture was partitioned by the addition of 200 mL methyl tert-butyl ether and 30 mL 5N sodium hydroxide. The aqueous phase was extracted with 100 mL methyl tert-butyl ether followed by 100 mL dichloromethane. The organic phases were combined, washed with 50 mL 1M sodium hydroxide followed by saturated aqueous sodium chloride, dried over

A solution of 64 gm (209 mMol) S-(3-fluoro-2-bromophen-
yl)-N,N-diethylthiocarbamate in 800 mL methanol was treated
with 80 gm (1.21 mMol) 85% potassium hydroxide. The
addition resulted in an exotherm from 22°C to 53°C over 10
minutes. The reaction mixture was maintained at 50°C for 2
hours and then 91.7 gm (465 mMol) 2-bromoacetaldehyde
diethyl acetal were added. After 22 hours the reaction
mixture was cooled to room temperature and was then
partitioned by the addition of 800 mL methyl tert-butyl
ether and 800 mL water. The organic phase was washed with
200 mL 2M aqueous sodium bisulfate, dried over sodium
sulfate, and concentrated under reduced pressure. The
residue was used without further purification.

A solution of 8.1 gm (28 mMol) 2-trimethylsilyl-7-bromobenzothiophene in 60 mL tetrahydrofuran was cooled to -78°C. This solution was then treated with 23.1 mL (37 mMol) *n*-butyllithium (1.6 M in hexane) and stirred for 15 minutes. A solution of 5.18 gm (25 mMol) 1-benzyl-3-methyl-4-oxopiperidine in 20 mL tetrahydrofuran was then added dropwise. The reaction mixture was stirred for about 20 hours, gradually warming to room temperature. The reaction mixture was then diluted with water and extracted well with ethyl acetate. The organic extracts were combined, dried over sodium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with 20% ethyl acetate in hexane. Fractions containing the desired compound were combined and concentrated under reduced pressure to provide 5.1 gm (50%)

-45-

1-benzyl-3-methyl-4-(benzothien-7-yl)-1,2,3,6-tetrahydropyr-
idine and 1-benzyl-3-methyl-4-(benzothien-7-yl)-1,2,5,6-
tetrahydropyridine

A mixture of 5.1 gm (12.5 mMol) 1-benzyl-3-methyl-4-
5 hydroxy-4-(2-trimethylsilylbenzothien-7-yl)piperidine and
5.93 gm (31 mMol) p-toluenesulfonic acid monohydrate was
heated at reflux for about 3 hours. The reaction mixture
was cooled to room temperature and diluted with ethyl
acetate. This mixture was washed 2 x 100 mL 2N sodium
10 hydroxide, dried over sodium sulfate and concentrated under
reduced pressure. The residue was subjected to silica gel
chromatography, eluting with 20% ethyl acetate in hexane.

Fractions containing 1-benzyl-3-methyl-4-(benzothien-7-
yl)-1,2,3,6-tetrahydropyridine were combined and concen-
15 trated under reduced pressure to provide 1.37 gm (34.3%).

Fractions containing 1-benzyl-3-methyl-4-(benzothien-7-
yl)-1,2,5,6-tetrahydropyridine were combined and
concentrated under reduced pressure to provide 0.11 gm
(2.6%).

20 Later fractions were combined and concentrated under
reduced pressure to provide 1.96 gm (47%) 1-benzyl-3-methyl-
4-hydroxy-4-(benzothien-7-yl)piperidine.

Debenzylation/Salt formation

25 A solution of 1.37 gm (4.3 mMol) 1-benzyl-3-methyl-4-
(benzothien-7-yl)-1,2,3,6-tetrahydropyridine in 20 mL
dichloromethane was cooled to 0°C. This solution was
treated with 0.92 mL (8.56 mMol) 1-chloroethyl chloroformate
dropwise. The reaction mixture was stirred for two hours,
30 warming gradually to room temperature. The reaction mixture
was then concentrated under reduced pressure and the residue
dissolved in 20 mL methanol. This solution was heated at
reflux for 2 hours and was then concentrated under reduced

-46-

pressure. This residue was subjected to silica gel chromatography. Fractions containing product were combined and concentrated under reduced pressure to provide 0.73 gm 3-methyl-4-(benzothien-7-yl)-1,2,3,6-tetrahydropyridine.

- 5 This material was treated with hydrogen chloride in diethyl ether to provide 3-methyl-4-(benzothien-7-yl)-1,2,3,6-tetrahydropyridine hydrochloride.

m.p. = 150-155°C

- Beginning with 0.10 gm (0.31 mMol) 1-benzyl-3-methyl-4-(benzothien-7-yl)-1,2,5,6-tetrahydropyridine, 0.032 gm 3-methyl-4-(benzothien-7-yl)-1,2,5,6-tetrahydropyridine was prepared as described in the previous paragraph. This material was treated with oxalic acid to provide 3-methyl-4-(benzothien-7-yl)-1,2,5,6-tetrahydropyridine oxalate.

- 15 m.p. = 201-203°C

EA: Calculated for: $C_{14}H_{15}NS \cdot C_2H_2O_4$: C, 60.17; H, 5.37; N, 4.39. Found: C, 59.94; H, 5.49; N, 4.62.

EXAMPLE 2

- 20 3,3-dimethyl-4-(benzothien-7-yl)-1,2,3,6-tetrahydropyridine hydrochloride

Beginning with 2-trimethylsilyl-7-bromobenzothiophene and 1-benzyl-3,3-dimethyl-4-oxopiperidine, the title compound was prepared essentially as described in EXAMPLE 1.

- 25 m.p. = 204-206°C

EA: Calculated for: $C_{15}H_{17}NS \cdot HCl$: C, 64.38; H, 6.48; N, 5.00; S, 11.46. Found: C, 64.70; H, 6.55; N, 5.23; S, 11.55.

-47-

EXAMPLE 3

3,3-dimethyl-4-(4-fluorobenzothien-7-yl)-1,2,3,6-tetrahydropyridine hydrochloride

5 Beginning with 2-trimethylsilyl-4-fluoro-7-bromobenzo-
thiophene and 1-benzyl-3,3-dimethyl-4-oxopiperidine, the
title compound was prepared essentially as described in
EXAMPLE 1.

m.p. = 240-242°C

10 Ion Spray MS: m/e = 262 (M+1)

High Resolution MS: Theory: 262.1065. Found: 262.1074.

EXAMPLE 4

cis-3-methyl-4-(6-fluorobenzothien-7-yl)piperidine oxalate
15 1-benzyl-3-methyl-4-hydroxy-4-(2-trimethylsilyl-6-fluoro-
benzothien-7-yl)piperidine

A solution of 1.12 gm (5.0 mMol) 2-trimethylsilyl-6-fluorobenzothiophene in 5.6 mL tetrahydrofuran was cooled to -78°C. A solution of 3.2 mL (5.5 mMol) tert-butyllithium
20 (1.7 M in pentane) was added dropwise over 20 minutes. Once the addition was complete, the reaction mixture was stirred for 1 hour and then a solution of 1.12 gm (5.5 mMol) 1-benzyl-3-methyl-4-oxopiperidine in 3.6 mL tetrahydrofuran was added dropwise over 10 minutes. The cooling bath was
25 removed and the reaction mixture was stirred for 1 hour, gradually warming to room temperature. The reaction mixture was then treated with 5 mL saturated aqueous ammonium chloride followed by 5 mL water. This mixture was extracted with 3 x 25 mL ethyl acetate. The organic extracts were
30 combined, washed with saturated aqueous sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residue gradually began to crystallize. The crystalline mass was dissolved in 25 mL diethyl ether and

-48-

was heated at reflux. To this heated solution were added 30 mL hexane, and the mixture reduced in volume until most of the diethyl ether was removed. The solution was then cooled to room temperature. The crystals which formed were
5 collected by filtration to provide 1.10 gm of the desired compound.

EA: Calculated for: $C_{24}H_{29}NOSFSi$: C, 67.41; H, 7.07; N, 3.28. Found: C, 67.51; H, 7.01; N, 3.42.

10 1-benzyl-3-methyl-4-(methyl oxoacetox)-4-(2-trimethylsilyl-6-fluorobenzothien-7-yl)piperidine

A solution of 0.47 gm (1.15 mMol) 1-benzyl-3-methyl-4-hydroxy-4-(2-trimethylsilyl-6-fluorobenzothien-7-yl)piperidine and 0.42 gm (3.45 mMol) 4-(dimethylamino)pyridine in 3
15 mL dichloromethane was cooled in an ice water bath. To this mixture were added 0.32 mL (3.45 mMol) methyl chlorooxoacetate and the resulting mixture was stirred for 7 hours at room temperature. The reaction mixture was poured into a mixture of 15 mL dichloromethane and 15 mL ice water. The
20 phases were separated and the aqueous phase was extracted with 20 mL dichloromethane. The combined organic phases were washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure to provide a white solid.

25 cis-1-benzyl-3-methyl-4-(2-trimethylsilyl-6-fluorobenzothien-7-yl)piperidine

A solution of 0.57 gm (1.15 mMol) 1-benzyl-3-methyl-4-(methyl oxoacetox)-4-(2-trimethylsilyl-6-fluorobenzothien-
30 7-yl)piperidine, 0.62 mL (2.3 mMol) tri(n-butyl)tin hydride, and 0.10 gm (0.58 mMol) 2,2'-azobisisobutyronitrile in 6 mL of toluene was stirred at reflux for about 2.5 hours. The

-49-

reaction mixture was concentrated under reduced pressure and the residue subjected to radial silica gel chromatography (4 mm plate), eluting first with hexane and then with 25% ethyl acetate in hexane. Fractions containing the desired
5 compound were combined and concentrated under reduced pressure to provide 0.157 gm (34%).

cis-1-benzyl-3-methyl-4-(6-fluorobenzothien-7-yl)piperidine

A mixture of 0.15 gm (0.36 mMol) cis-1-benzyl-3-methyl-
10 4-(2-trimethylsilyl-6-fluorobenzo-thien-7-yl)piperidine and 0.20 gm (1.07 mMol) p-toluenesulfonic acid monohydrate in 20 mL toluene was heated at 100°C for 3 hours. The reaction mixture was then cooled to room temperature and diluted with 50 mL ethyl acetate. This mixture was washed sequentially
15 with 3 x 25 mL 0.2 N sodium hydroxide and 25 mL saturated aqueous sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residue was subjected to radial silica gel chromatography (2 mm plate), eluting with 25% ethyl acetate in hexane. Fractions
20 containing product were combined and concentrated under reduced pressure to provide 0.11 gm of the desired compound.

Debenzylation/salt formation

Beginning with 0.11 gm (0.30 mMol) cis-1-benzyl-3-
25 methyl-4-(6-fluorobenzothien-7-yl)piperidine, 0.080 gm of cis-3-methyl-4-(6-fluorobenzothien-7-yl)piperidine were prepared essentially as described in EXAMPLE 1. Treatment of this compound with oxalic acid in acetone provided 0.058 gm of the title compound.

30 Ion Spray MS: m/e = 250 (M+1)

EA: Calculated for: C₁₄H₁₆NSF-C₂H₂O₄: C, 56.62; H, 5.35; N, 4.13. Found: C, 56.61; H, 5.54; N, 3.92.

-50-

EXAMPLE 5

cis-3-ethyl-4-(benzothien-7-yl)piperidine hydrochloride
1-benzyl-3-methyl-4-hydroxy-4-(2-trimethylsilylbenzothien-7-
yl)piperidine

5 Beginning with 1.4 gm (4.9 mMol) 2-trimethylsilyl-7-bromobenzofuran and 1.0 gm (4.7 mMol) 1-benzyl-3-ethyl-4-oxopiperidine, 0.67 gm (37%) of the desired compound were prepared essentially as described in EXAMPLE 4.

Ion Spray MS: m/e = 424 (M+1)

10 EA: Calculated for: C₂₄H₃₀NOSSi: C, 70.87; H, 7.85; N, 3.30. Found: C, 71.20; H, 7.99; N, 3.33.

cis-1-benzyl-3-ethyl-4-(2-trimethylsilylbenzothien-7-
yl)piperidine

15 Beginning with 0.65 gm 1-benzyl-3-ethyl-4-hydroxy-4-(2-trimethylsilylbenzothien-7-yl)piperidine, 0.72 gm 1-benzyl-3-ethyl-4-(methyl oxoacetoxy)-4-(2-trimethylsilylbenzothien-7-yl)piperidine were prepared essentially as described in EXAMPLE 4.

20 Ion Spray MS: m/e = 510 (M+1)

Beginning with 0.71 gm 1-benzyl-3-ethyl-4-(methyl oxoacetoxy)-4-(2-trimethylsilylbenzothien-7-yl)piperidine, 0.20 gm of the desired compound were prepared essentially as described in EXAMPLE 4.

25 Ion Spray MS: m/e = 408 (M+1)

cis-3-ethyl-4-(2-trimethylsilylbenzothien-7-yl)piperidine

Beginning with 0.19 gm (0.56 mMol) cis-1-benzyl-3-methyl-4-(2-trimethylsilylbenzothien-7-yl)piperidine, 0.10 gm (68%) of the desired compound were prepared essentially as described in EXAMPLE 4.

30

-51-

Desilylation/salt formation

Beginning with 0.10 gm (0.31 mMol) cis-3-ethyl-4-(2-trimethylsilylbenzothien-7-yl)piperidine, 0.05 gm (56%) of the title compound were prepared as an off-white powder
5 essentially as described in EXAMPLE 4.

EXAMPLE 6

cis-3-methyl-4-(5-fluorobenzothien-7-yl)piperidine
hydrochloride

10 1-benzyl-3-methyl-4-hydroxy-4-(5-fluorobenzothien-7-yl)piperidine

A suspension of 0.24 gm (10 mMol) magnesium turnings in 20 mL tetrahydrofuran was sonicated under nitrogen for 10 minutes. A solution of 1.85 gm (8 mMol) 5-fluoro-7-bromo-
15 benzothiophene in 5 mL tetrahydrofuran was added followed by two drops of 1,2-dibromoethane. The mixture was sonicated as temperature rose to 45-50°C. The reaction mixture was stirred for about 1.5 hours and was then cooled in an ice bath. A solution of 2.15 gm (10.6 mMol) 1-benzyl-3-methyl-
20 4-oxopiperidine in 5 mL tetrahydrofuran was then added dropwise. The reaction mixture was allowed to warm to room temperature and was then heated at 40-50°C for about 18 hours. The reaction mixture was cooled in an ice bath and was quenched with saturated aqueous ammonium chloride and
25 ice. This mixture was then extracted well with ethyl acetate. The organic extracts were combined, washed with saturated aqueous sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with a
30 gradient of dichloromethane containing from 0-8% methanol. Fractions containing product were combined and concentrated under reduced pressure to provide 0.78 gm of the desired compound in two portions.

30

-53-

EXAMPLE 8

3,3-dimethyl-4-(benzothien-7-yl)piperidine oxalate

Beginning with 7-bromobenzothiophene and 1-benzyl-3,3-dimethyl-4-oxopiperidine, the title compound was prepared essentially as described in EXAMPLE 6.

m.p. = 192-195°C

Ion Spray MS: m/e = 246 (M+1)

EXAMPLE 9

3-methyl-4-(benzothien-4-yl)piperidine hydrochloride

Beginning with a mixture of 4-bromobenzothiophene and 6-bromobenzothiophene, and 1-benzyl-3-methyl-4-oxopiperidine, the title compound was prepared essentially as described in EXAMPLE 6. The desired compound was separated by chromatography from the isomeric mixture after the mixture had been debenzylated in the final step of the synthesis.

m.p. >280°C

High Resolution MS: Theory: 232.1160. Found: 232.1172.

EXAMPLE 10

2-methyl-4-(benzothien-7-yl)piperidine hydrochloride

Beginning with 2-(trimethylsilyl)-7-bromobenzofuran and 1-allyl-2-methyl-4-oxopiperidine, 1-allyl-2-methyl-4-(benzothien-7-yl)piperidine was prepared essentially as described in EXAMPLE 4. The allyl group was removed by heating a mixture of 0.166 gm (0.61 mMol) 1-allyl-2-methyl-4-(benzothien-7-yl)piperidine and 0.003 gm tris(triphenylphosphine)rhodium(I) chloride in 9 mL ethanol to reflux, removing solvent by distillation. Once 2.5 mL solvent had been removed, an additional 2.5 mL solvent and .0025 gm tris(triphenylphosphine)rhodium(I) chloride were added and an additional 2.5 mL solvent were removed by distillation.

-54-

This cycle was repeated two more times and then the reaction mixture was cooled to room temperature. This cooled mixture was then poured over a Varian SCX column, eluting sequentially with 5 x 20 mL methanol, and 2M ammonium
5 hydroxide in methanol. Fractions containing the desired compound were combined and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with ethyl acetate containing 10% 2M ammonium hydroxide in methanol. Fractions containing
10 product were combined and concentrated under reduced pressure to provide 0.07 gm (47%) of a tan oil. This oil was dissolved in diethyl ether and treated with diethyl ether containing hydrogen chloride. The precipitate which formed was collected by filtration and dried to provide 0.5
15 gm of the title compound as a white powder.
m.p. = 237-238°C
MS: m/e = 232 (M+1)

EXAMPLE 11

20 3-methyl-4-(4-fluorobenzothien-7-yl)piperidine hydrochloride
Beginning with 2-(trimethylsilyl)-4-fluoro-7-bromobenzothiophene and 1-benzyl-3-methyl-4-oxopiperidine, the title compound was prepared essentially as described in EXAMPLE 4.
m.p. >320°C
25 MS: m/e = 250 (M+1)

EXAMPLE 12

3,3-dimethyl-4-(5-fluorobenzothien-7-yl)-1,2,3,6-tetrahydro-
pyridine fumarate
30 Beginning with 2-trimethylsilyl-5-fluoro-7-bromobenzothiophene and 1-(tert-butoxycarbonyl)-3,3-dimethyl-4-oxopiperidine, the title compound was prepared essentially as described in EXAMPLE 1.

-55-

MS: m/e = 262.

EXAMPLE 13

3,3-dimethyl-4-(6-fluorobenzothien-7-yl)-1,2,3,6-tetrahydro-
pyridine hydrochloride

5 A solution of 4.35 gm (19.4 mMol) 2-trimethylsilyl-6-fluorobenzothiophene in 22 mL tetrahydrofuran was cooled to -78°C. To this cooled solution were added 12.5 mL (21.3 mMol) tert-butyllithium (1.7 M in pentane) dropwise over 70
10 minutes. The reaction mixture was stirred an additional 15 minutes and then a solution of 4.63 gm (21.3 mMol) 1-benzyl-3,3-dimethylpiperidin-4-one in 13 mL tetrahydrofuran was added dropwise over 20 minutes. Once the addition was complete, the cooling bath was removed and the reaction
15 mixture allowed to warm to room temperature over two hours. The mixture was then treated with 5 mL saturated aqueous ammonium chloride followed by water. The mixture was extracted 2 x 25 mL ethyl acetate. The organic phases were combined, washed with saturated aqueous sodium chloride,
20 dried over magnesium sulfate and concentrated under reduced pressure. The residue was subjected to radial chromatography (silica gel, 4mm plate), eluting with hexane at a rate of 9 mL/minute and then 3:1 acetone:hexane. Fractions containing product were combined and concentrated
25 under reduced pressure to provide 4.13 gm of an oil. This oil was dissolved in 36 mL ethanol and was treated with 1.06 gm sodium borohydride. The mixture was stirred 45 minutes at room temperature and was then quenched with water. The mixture was extracted 2 x 50 mL ethyl acetate. The organic
30 phases were combined, washed with saturated aqueous sodium chloride, dried over sodium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with 15% ethyl acetate in toluene.

A suspension of 1.75 gm (8.12 mMol) 4-(benzothien-4-yl)-1,2,5,6-tetrahydropyridine and 1.8 gm 10% palladium on carbon in 50 mL ethanol was hydrogenated for 2 days at 50°C and 45 p.s.i and 2 additional days at room temperature and 45 p.s.i. After the first day, an additional 2 gm 10% palladium on carbon were added to the reaction mixture. The

-59-

reaction mixture was filtered and the filtrate concentrated under reduced pressure to provide 0.49 gm (28%) of the desired compound as a clear oil.

MS: $m/e = 218$ (M+1)

5

1-chloro-4-(benzothien-4-yl)piperidine

A solution of 0.47 gm (2.17 mMol) 4-(benzothien-4-yl)piperidine in 8 mL tetrahydrofuran and 4 mL diethyl ether was cooled to 0°C. To this solution were added 0.30 gm N-chlorosuccinimide and the reaction mixture was allowed to warm to room temperature. After 1 hour the reaction mixture was concentrated under reduced pressure and the residue partitioned with diethyl ether and aqueous sodium bicarbonate. The phases were separated and the aqueous phase extracted well with diethyl ether. The organic phases were combined, dried over sodium sulfate, and concentrated under reduced pressure to provide 0.41 gm of the desired compound.

20 Imine formation/methylation

A mixture of 0.38 gm (1.51 mMol) 1-chloro-4-(benzothien-4-yl)piperidine, 0.008 gm 18-crown-6, and 0.28 gm (3.92 mMol) potassium superoxide in 5 mL diethyl ether was stirred at room temperature overnight. The mixture was filtered and the filter cake washed with diethyl ether. The filtrate was added slowly to a solution of 2.7 mL (3.77 mMol) methyllithium (1.4 M in diethyl ether) in 3 mL diethyl ether. The reaction mixture was stirred for 1 hour at room temperature and was then slowly diluted with water. The resulting mixture was extracted well with diethyl ether and then once with ethyl acetate. The combined organic extracts were dried over sodium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel

A mixture of 3.115 gm (13.6 mMol) 2-methyl-4-(benzothien-4-yl)-1,2,3,6-tetrahydropyridine and 3.2 gm Royer palladium catalyst in 40 mL methanol was hydrogenated on a Parr shaker at 50°C and 45 p.s.i. for 24 hours. At this point an additional 4 gm of Royer palladium catalyst were added and the hydrogenation continued for an additional 40 hours. The reaction mixture was filtered, the solid washed with methanol, and the combined filtrates

-61-

concentrated under reduced pressure. The residue was subjected to silica gel chromatography, eluting with a gradient of dichloromethane containing from 0-4% methanol and a trace of ammonia. Fractions containing product were
5 combined and concentrated under reduced pressure to provide 1.46 gm (46%) of cis-2-methyl-4-(benzofur-4-yl)piperidine as a yellow oil.

MS: m/e = 232 (M+1)

The title compound was prepared by treating this material
10 with succinic acid.

The ability of the compounds of this invention to bind to the 5-HT_{2C} receptor subtype was measure essentially as described by Wainscott (Wainscott, et al., Journal of
15 Pharmacology and Experimental Therapeutics, **276**, 720-727 (1996)).

Membrane Preparation

AV12 cells stably transfected with the human 5-HT_{2C}
20 receptors were grown in suspension and harvested by centrifugation, resuspended in 50 mM tris-HCl, pH 7.4, and frozen at -70°C. On the day of assay, an aliquot of cells was thawed, resuspended in 40 mL of 50 mM tris-HCl, pH 7.4, and centrifuged at 39,800 x g for 10 minutes at 4°C. The
25 resulting pellet was resuspended, incubated at 37°C for 10 minutes to remove endogenous serotonin, then centrifuged twice more.

-62-

[¹²⁵I]-DOI Binding for Determination of 5-HT_{2C} Receptor Affinity

Briefly, prepared cell membranes were added to dilutions of compounds in a final solution containing 50 mM tris-HCl, pH 7.4, 9.75 mM MgCl₂, 0.5 mM EDTA, 10 μM pargyline, 0.1% sodium ascorbate, and 0.1 nM [¹²⁵I]-DOI, with 10 μM mianserin for defining non-specific binding. All incubations (800 μL) were performed at 37°C for 30 minutes before harvesting onto GF/C filters prewet with 0.5% polyethyleneimine, with four 1 mL washes of ice-cold 50 mM tris-HCl, pH 7.4, and counting in a gamma counter. Nonlinear regression analysis was performed on the concentration response curves using a four parameter logistic equation described by DeLean (DeLean, et al., Molecular Pharmacology, **21**, 5-16 (1982)). IC₅₀ values were converted to K_i values using the Cheng-Prusoff equation (Cheng, et al., Biochem. Pharmacol., **22**, 3099-3108 (1973)).

Representative compounds of the present invention were found to have affinity for the 5-HT_{2C} receptor as measured essentially by the procedure described supra.

The 5-HT_{2C} receptor is functionally coupled to specific G-proteins. Agonist activation of 5-HT_{2C} G-protein-coupled receptors results in the release of GDP from the •-subunit (G alpha q or G alpha i) of the G-protein and the subsequent binding of GTP. The binding of the stable analog [³⁵S]-GTPγS is an indicator of this receptor's activation.

[³⁵S]-GTPγS binding

30

The immunoadsorption scintillation proximity assay (ISPA) in microtiter plates of [³⁵S]-GTPγS binding to G alpha

-63-

q or G alpha i was modified from published conditions (DeLapp et al, JPET **289** (1999) 946-955). Test compounds were dissolved in DMSO and diluted in assay buffer consisting of 50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 100 mM NaCl, and 0.2 mM EGTA. Incubations were performed over 12 test concentrations; volume was 200 μ l. The incubation also contained 0.1 μ M GDP and 0.25 nM [³⁵S]-GTP γ S. Membrane homogenates from AV12 cells stably transfected with the human 5-HT_{2C} receptor were added and the microtiter plates were incubated for 30 minutes at room temperature. The incubation was terminated by the addition of Nonidet P-40 (final concentration of 0.27%), followed by addition of rabbit polyclonal anti-G alpha q/11 antibody (0.2 μ g per well), and anti-rabbit scintillation proximity assay beads (Amersham; 1.25 mg per well; final volume was 290 μ l). The mixture was incubated for 3 hours at room temperature to complete the immunoadsorption of [³⁵S]-GTP γ S bound to G alpha q/11. Microtiter plates were centrifuged briefly to pellet beads. [³⁵S]-GTP γ S binding was quantitated by microtiter plate scintillation spectrometry (Wallac). Data analysis was performed by nonlinear regression analysis with GraphPad Prism software running on a personal computer, using 5-HT control concentration-response curves to define maximal stimulation of [³⁵S]-GTP γ S binding.

Representative compounds of the present invention were tested in the [³⁵S]-GTP γ S assay and were found to be agonists of the 5-HT_{2C} receptor.

The ability of agonists of the 5-HT_{2C} receptor in general, and the compounds of the present invention in

-64-

particular, to treat obesity is demonstrated by testing in a feeding assay.

Fasted Feeding Assay

Male rats were fasted for 18 hours prior to testing.
 5 Rats were first assigned to either a treatment or control group (N=8), then weighed, administered drug or vehicle orally, and returned to their home cage. Thirty minutes later, food was made available to the animals. The the food and the food hopper was weighed before, one hour, two hours,
 10 and four hours after food was made available to the test animals. Weight of food consumed plus spillage by the treatment animals was compared to food consumed plus spillage by control animals using a one-way ANOVA, with a Dunnett's post-hoc test.

15 Representative compounds of the present invention were tested in the feeding assay and were found to reduce food consumed by fasting rats.

While it is possible to administer a compound employed
 20 in the methods of this invention directly without any formulation, the compounds are usually administered in the form of pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one active ingredient. These compositions can be administered
 25 by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Many of the compounds employed in the methods of this invention are effective as both injectable and oral compositions. Such compositions are prepared in a manner
 30 well known in the pharmaceutical art and comprise at least

- 65 -

one active compound. See, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES, (16th ed. 1980).

In making the compositions employed in the present invention the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents

-66-

such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after
5 administration to the patient by employing procedures known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 0.05 to about 100 mg, more usually about 1.0 to about 30 mg, of the active
10 ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with
15 a suitable pharmaceutical excipient.

The active compounds are generally effective over a wide dosage range. For examples, dosages per day normally fall within the range of about 0.01 to about 30 mg/kg. In the treatment of adult humans, the range of about 0.1 to
20 about 15 mg/kg/day, in single or divided dose, is especially preferred. However, it will be understood that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of
25 administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way. In
30 some instances dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are

-67-

first divided into several smaller doses for administration throughout the day.

Formulation Example 1

5

Hard gelatin capsules containing the following ingredients are prepared:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
10	Compound of Example 1	30.0
	Starch	305.0
15	Magnesium stearate	5.0

The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

20

Formulation Example 2

A tablet formula is prepared using the ingredients below:

	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/tablet)</u>
25	Compound of Example 2	25.0
30	Cellulose, microcrystalline	200.0
	Colloidal silicon dioxide	10.0

-68-

Stearic acid 5.0

The components are blended and compressed to form tablets, each weighing 240 mg.

5

Formulation Example 3

A dry powder inhaler formulation is prepared containing the following components:

10

<u>Ingredient</u>	<u>Weight %</u>
Compound of Example 3	5
15 Lactose	95

The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

20

Formulation Example 4

Tablets, each containing 30 mg of active ingredient, are prepared as follows:

25

<u>Ingredient</u>	<u>Quantity (mg/tablet)</u>
Compound of Example 4	30.0 mg
30 Starch	45.0 mg
Microcrystalline cellulose	35.0 mg

- 69 -

	Polyvinylpyrrolidone	
	(as 10% solution in water)	4.0 mg
	Sodium carboxymethyl starch	4.5 mg
5	Magnesium stearate	0.5 mg
	Talc	<u>1.0 mg</u>
10	Total	120 mg

The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.

Formulation Example 5

25

Capsules, each containing 40 mg of medicament are made as follows:

30	<u>Ingredient</u>	<u>Quantity</u> <u>(mg/capsule)</u>
	Compound of Example 5	40.0 mg

WO 01/09126

PCT/US00/17864

-70-

	Starch	109.0 mg
	Magnesium stearate	<u>1.0 mg</u>
5	Total	150.0 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in
10 150 mg quantities.

Formulation Example 6

Suppositories, each containing 25 mg of active
15 ingredient are made as follows:

	<u>Ingredient</u>	<u>Amount</u>
	Compound of Example 6	25 mg
20	Saturated fatty acid glycerides to	2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid
25 glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

WO 01/09126

PCT/US00/17864

-71-

Formulation Example 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

5

<u>Ingredient</u>	<u>Amount</u>
Compound of Example 7	50.0 mg
10 Xanthan gum	4.0 mg
Sodium carboxymethyl cellulose (11%)	
Microcrystalline cellulose (89%)	50.0 mg
15 Sucrose	1.75 g
Sodium benzoate	10.0 mg
Flavor and Color	q.v.
20 Purified water to	5.0 ml

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

30

	<u>Ingredient</u>	<u>Quantity</u>
30	Compound of Example 9	250.0 mg
	Isotonic saline	1000 ml

-73-

Formulation Example 10

A topical formulation may be prepared as follows:

5	<u>Ingredient</u>	<u>Quantity</u>
	Compound of Example 1	1-10 g
	Emulsifying Wax	30 g
10	Liquid Paraffin	20 g
	White Soft Paraffin	to 100 g

15 The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.

20

-74-

Formulation Example 11

Sublingual or buccal tablets, each containing 10 mg of active ingredient, may be prepared as follows:

5			Quantity
	<u>Ingredient</u>		<u>Per Tablet</u>
	Compound of Example 4		10.0 mg
10	Glycerol		210.5 mg
	Water		143.0 mg
15	Sodium Citrate		4.5 mg
	Polyvinyl Alcohol		26.5 mg
	Polyvinylpyrrolidone		15.5 mg
20	Total		410.0 mg

The glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90°C. When the polymers have gone into solution, the solution is cooled to about 50-55°C and the medicament is slowly admixed. The homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.

Another preferred formulation employed in the methods of the present invention employs transdermal

-75-

delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of biological factors to specific anatomical regions of the body, is described in U.S. Patent 5,011,472, issued April 30, 1991, which is herein incorporated by reference.

Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.

WO 01/09126

PCT/US00/17864


-76-

The type of formulation employed for the administration of the compounds employed in the methods of the present invention may be dictated by the particular compounds employed, the type of
5 pharmacokinetic profile desired from the route of administration and the compound(s), and the state of the patient.

-77-

WE CLAIM:

1. The compounds of Formula I:



I


where:

R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

10 R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;


15 R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



20

(i)



-80-

taken together with the carbon atoms to which they are attached form a double bond;


$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;

5 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and

b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$
10 may be other than hydrogen.

3. A method for increasing activation of the 5-HT_{2C} receptor in mammals, comprising administering to a mammal in need of such activation a pharmaceutically effective amount
15 of a compound of Formula I:



where:

R is hydrogen, halo, trifluoromethyl or C_1 - C_6 alkyl;


R^1 is hydrogen, halo, trifluoromethyl, phenyl, or C_1 - C_6
20 alkyl;

R^2 , R^3 , and R^4 are independently hydrogen, halo, trifluoromethyl, cyano, C_1 - C_4 alkoxy, C_1 - C_4 alkoxycarbonyl, C_1 - C_6 alkyl, C_1 - C_6 alkyl substituted with a substituent selected from the group consisting of C_1 - C_4 alkoxy and
25 hydroxy, or $-C(O)NHR^9$;

-81-

R^9 is C_1 - C_8 alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the
5 benzofuran nucleus and is an amine of formula:



(i)

n is 0, 1, or 2;

10 R^5 , R^6 , and R^7 are independently hydrogen or C_1 - C_4 alkyl;

Q is hydrogen;

$R^{5'}$ is hydrogen or methyl, provided that $R^{5'}$ may be methyl only when R^5 is other than hydrogen, or $R^{5'}$ and Q
15 taken together with the carbon atoms to which they are attached form a double bond;

$R^{6'}$ is hydrogen or methyl, provided that $R^{6'}$ may be methyl only when R^6 is other than hydrogen, or $R^{6'}$ and Q
20 taken together with the carbon atoms to which they are attached form a double bond;

$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;


or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

25 a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and

b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$ may be other than hydrogen.

-82-

4. A method for the treatment of obesity in mammals, comprising administering to a mammal in need of such treatment an effective amount of a compound of Formula I:



I

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

10 R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and
15 hydroxy, or -C(O)NHR⁹;

R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

20 A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



-83-

(i)

n is 0, 1, or 2;

R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

5 Q is hydrogen;

R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

10 R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q taken together with the carbon atoms to which they are attached form a double bond;


15 R^{7'} is hydrogen or methyl, provided that R^{7'} may be methyl only when R⁷ is other than hydrogen;

or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R⁵, R⁶, and R⁷, must be other than hydrogen; and

20 b) no more than two of R⁵, R^{5'}, R⁶, R^{6'}, R⁷, and R^{7'} may be other than hydrogen.

5. A method for the treatment of depression in mammals, comprising administering to a mammal in need of
25 such treatment an effective amount of a compound of Formula I:



WO 01/09126

PCT/US00/17864

-84-

where:


R is hydrogen, halo, trifluoromethyl or C₁-C₆ alkyl;

R¹ is hydrogen, halo, trifluoromethyl, phenyl, or C₁-C₆ alkyl;

5 R², R³, and R⁴ are independently hydrogen, halo, trifluoromethyl, cyano, C₁-C₄ alkoxy, C₁-C₄ alkoxycarbonyl, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with a substituent selected from the group consisting of C₁-C₄ alkoxy and hydroxy, or -C(O)NHR⁹;

10 R⁹ is C₁-C₈ alkyl where the alkyl chain is optionally substituted with a substituent selected from the group consisting of phenyl and pyridyl;

A is attached at either the 4- or 7-position of the benzofuran nucleus and is an amine of formula:



15

(i)

n is 0, 1, or 2;

20 R⁵, R⁶, and R⁷ are independently hydrogen or C₁-C₄ alkyl;

Q is hydrogen;

25 R^{5'} is hydrogen or methyl, provided that R^{5'} may be methyl only when R⁵ is other than hydrogen, or R^{5'} and Q taken together with the carbon atoms to which they are attached form a double bond;

R^{6'} is hydrogen or methyl, provided that R^{6'} may be methyl only when R⁶ is other than hydrogen, or R^{6'} and Q

-85-

taken together with the carbon atoms to which they are attached form a double bond;

$R^{7'}$ is hydrogen or methyl, provided that $R^{7'}$ may be methyl only when R^7 is other than hydrogen;

5 or pharmaceutically acceptable acid addition salts thereof subject to the following provisos:

a) when n is 1 or 2, at least one of R^5 , R^6 , and R^7 , must be other than hydrogen; and

10 b) no more than two of R^5 , $R^{5'}$, R^6 , $R^{6'}$, R^7 , and $R^{7'}$ may be other than hydrogen.

6. A method of any of Claims 3, 4, or 5 where the mammal is human.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/09126 A1

(51) International Patent Classification⁷: **C07D 409/04**,
A61K 31/4535, A61P 25/24, 3/04

(21) International Application Number: PCT/US00/17864

(22) International Filing Date: 21 July 2000 (21.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/146,185 29 July 1999 (29.07.1999) US
60/172,784 20 December 1999 (20.12.1999) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRINER, Karin** [CH/US]; 7649 Pinesprings East Drive, Indianapolis, IN 46256 (US); **BURKHOLDER, Timothy, Paul** [US/US]; 13904 Springmill Ponds Circle, Carmel, IN 46032 (US); **CONWAY, Richard, Gerard** [US/US]; 121 Lark Drive, Apartment C, Carmel, IN 46032 (US); **CUNNINGHAM, Brian, Eugene** [US/US]; 5433 Fox Way, Apartment 3, Indianapolis, IN 46237 (US); **FINLEY, Don, Richard** [US/US]; 4644 Macy Drive, Greenwood, IN 46142 (US); **HEINZ, Lawrence, Joseph** [US/US]; 212 Fawn Court, Pittsboro, IN 46167 (US); **JESUDASON, Cynthia, Darshini** [LK/US]; 3080 Bentwood Circle South Drive #1A, Indianapolis, IN 46268 (US); **KOHLMAN, Daniel**,

Timothy [US/US]; 6281 East Old Otto Court, Camby, IN 46113 (US); **LIANG, Sidney, Xi** [CN/US]; 8430 Harrison Parkway, Fishers, IN 46038 (US); **XU, Yao-Chang** [CA/US]; 10815 Timber Springs Drive East, Fishers, IN 46038 (US).

(74) Agents: **TITUS, Robert, D.** et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SEROTONERGIC BENZOTHIOPHENES



(I)

(57) Abstract: The present invention provides serotonergic benzothiophenes of Formula (I), where A, R, R¹, R², R³, and R⁴ are as described in the specification.

WO 01/09126 A1



1.00031311.00000000

Please type a plus sign (+) inside this box

□



PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION	Attorney Docket Number	X-12591	
	First Named Inventor	Karin Briner	
	COMPLETE IF KNOWN		
	Application Number		
	Filing Date		
	Group Art Unit		
<input type="checkbox"/> Declaration Submitted with Initial Filing	Examiner Name		
<input checked="" type="checkbox"/> Declaration Submitted after Initial Filing			

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SEROTONERGIC BENZOTHIOPHENES

the specification of which
☐ is attached hereto
OR
☒ was filed on (MM/DD/YYYY)

21 July 2000

 as United States Application Number or PCT International

Application Number

PCT/US00/17864

 and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
60/146,185 60/172,784	29 July 1999 20 December 1999	

Please type a plus sign (+) inside this box

☐

+

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney Name	Reg. No.
Arvie J. Anderson	45,263
Lynn D. Apelgren	45,341
Robert A. Armitage	27,417
Brian P. Barrett	39,597
Michael T. Bates	34,121
Roger S. Benjamin	27,025
Gary M. Birch	48,881
William R. Boudreaux	35,796
Steven P. Caltrider	36,467
Paul R. Cantrell	36,470
Charles E. Cohen	34,565
Donald L. Corneglio	30,741
Gregory A. Cox	47,504
Paula K. Davis	47,517
Elizabeth A. Dawalt	44,646
John C. Demeter	30,167
Manisha A. Desai	43,585
Joanne Longo Feeney	35,134
Paul J. Gaylo	36,808
Francis O. Ginah	44,712
Janet A. Gongola	48,436
Amy E. Hamilton	33,894
Frederick D. Hunter	26,915
Thomas E. Jackson	33,064
Charles Joyner	30,466
Gerald P. Keleher	43,707

Attorney Name	Reg. No.
James J. Kelley	41,888
Paul J. Koivuniemi	31,533
Robert E. Lee	27,919
Kirby Lee	47,744
James P. Leeds	35,241
Nelsen L. Lentz	38,537
Douglas K. Norman	33,267
Arlene Palmberg	40,422
Thomas G. Plant	35,784
Edward Prein	37,212
Grant E. Reed	41,264
James J. Sales	33,773
Michael J. Sayles	32,295
Robert L. Sharp	45,609
David M. Stemerick	40,187
Mark J. Stewart	43,936
Robert D. Titus	40,206
Robert C. Tucker	45,165
Tina M. Tucker	47,145
MaChari Vomdran-Jones	36,711
Gilbert T. Voy	43,972
Thomas D. Webster	39,872
Lawrence T. Welch	29,487
Alexander Wilson	45,782
Dan L. Wood	48,613

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	ELI LILLY AND COMPANY				
Address	ATTN: R. CRAIG TUCKER				
Address	LILLY CORPORATE CENTER/DC1104				
City	INDIANAPOLIS	State	INDIANA	ZIP	46285
Country		Telephone	(317) 433-9829	Fax	(317) 276-3861

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A Petition has been filed for this unsigned inventor

Given Name	Karin	Middle Name		Family Name	Briner	Suffix e.g. Jr.	
Inventor's Signature					Date		
Residence: City	Indianapolis	State	IN	Country	USA	Citizenship	Switzerland
Address	7649 Pinesprings East Drive						
Post Office Address	SAME AS ABOVE						
City	Indianapolis	State	IN	Zip	46256	Country	USA

☒ Additional Inventors are being named on supplement sheet(s) attached hereto.

Please type a plus sign (+) inside this box

□



PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor				
Given Name	Timothy			Middle Name	Paul	Family Name	Burkholder	Suffix e.g. Jr.
Inventor's Signature							Date	
Residence: City	Carmel			State	IN	Country	USA	Citizenship USA
Post Office Address	13904 Springmill Ponds Circle							
Post Office Address	SAME AS ABOVE							
City	Carmel			State	IN	Zip	46032	Country USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor				
Given Name	Richard			Middle Name	Gerard	Family Name	Conway	Suffix e.g. Jr.
Inventor's Signature							Date	
Residence: City	Carmel			State	IN	Country	USA	Citizenship USA
Post Office Address	121 Lark Drive, Apartment C							
Post Office Address	SAME AS ABOVE							
City	Carmel			State	IN	Zip	46032	Country USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor				
Given Name	Brian			Middle Name	Eugene	Family Name	Cunningham	Suffix e.g. Jr.
Inventor's Signature							Date	
Residence: City	Martinsville			State	IN	Country	USA	Citizenship USA
Post Office Address	6990 Red Day Road							
Post Office Address	SAME AS ABOVE							
City	Martinsville			State	IN	Zip	46151	Country USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor				
Given Name	Don			Middle Name	Richard	Family Name	Finley	Suffix e.g. Jr.
Inventor's Signature							Date	
Residence: City	Greenwood			State	IN	Country	USA	Citizenship USA
Post Office Address	4644 Macy Drive							
Post Office Address	SAME AS ABOVE							
City	Greenwood			State	IN	Zip	46142	Country USA

Please type a plus sign (+) inside this box

□

+

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**DECLARATION**

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Lawrence	Middle Name	Joseph	Family Name	Heinz	Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City	Pittsboro	State	IN	Country	USA	Citizenship	USA
Address	212 Fawn Court						
Post Office Address	SAME AS ABOVE						
City	Pittsboro	State	IN	Zip	46167	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Cynthia	Middle Name	Darshini	Family Name	Jesudason	Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City	Indianapolis	State	IN	Country	USA	Citizenship	Sri Lanka
Post Office Address	1090 Fleetwood Drive						
Post Office Address	SAME AS ABOVE						
City	Indianapolis	State	IN	Zip	46228	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Daniel	Middle Name	Timothy	Family Name	Kohlman	Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City	Camby	State	IN	Country	USA	Citizenship	USA
Post Office Address	6281 East Old Otto Court						
Post Office Address	SAME AS ABOVE						
City	Camby	State	IN	Zip	46113	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Sidney	Middle Name	Xi	Family Name	Liang	Suffix e.g. Jr.	
Inventor's Signature	<i>Sidney X Liang</i>					Date	1/16/02
Residence: City	Hamden	State	CT	Country	USA	Citizenship	USA
Address	1404 Aspen Glen Drive						
Post Office Address	SAME AS ABOVE						
City	Hamden	State	CT	Zip	06518	Country	USA

Please type a plus sign (+) inside this box

□

+

PTO/SB/01 (8-96) (MODIFIED)

SEE YMM 0 07 1100021311 050602

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

DECLARATION									
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Yao-Chang			Middle Name		Family Name	Xu		Suffix e.g. Jr.
Inventor's Signature							Date		
Residence: City	Fishers			State	IN	Country	USA		Citizenship Canada
Post Office Address	10815 Timber Springs Drive East								
Post Office Address	SAME AS ABOVE								
City	Fishers			State	IN	Zip	46038	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name				Middle Name		Family Name			Suffix e.g. Jr.
Inventor's Signature							Date		
Residence: City				State		Country			Citizenship
Post Office Address									
Post Office Address	SAME AS ABOVE								
City				State		Zip		Country	

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name				Middle Name		Family Name			Suffix e.g. Jr.
Inventor's Signature							Date		
Residence: City				State		Country			Citizenship
Address									
Post Office Address	SAME AS ABOVE								
City				State		Zip		Country	

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name				Middle Name		Family Name			Suffix e.g. Jr.
Inventor's Signature							Date		
Residence: City				State		Country			Citizenship
Post Office Address									
Post Office Address	SAME AS ABOVE								
City				State		Zip		Country	



10031311 030602

Please type a plus sign (+) inside this box

□

+

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION	Attorney Docket Number	X-12591	
	First Named Inventor	Karin Briner	
	COMPLETE IF KNOWN		
	Application Number		
	Filing Date		
	Group Art Unit		
<input type="checkbox"/> Declaration Submitted with Initial Filing	Examiner Name		
<input checked="" type="checkbox"/> Declaration Submitted after Initial Filing			

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SEROTONERGIC BENZOTHIOPHENES

the specification of which
☐ is attached hereto
OR
☒ was filed on 21 July 2000 as United States Application Number or PCT International

Application Number PCT/US00/17864 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached YES NO	
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/146,185	29 July 1999	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
60/172,784	20 December 1999	

Please type a plus sign (+) inside this box

+

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**DECLARATION**

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney Name	Reg. No.
Arvie J. Anderson	45,263
Lynn D. Apelgren	45,341
Robert A. Armitage	27,417
Brian P. Barrett	39,597
Michael T. Bates	34,121
Roger S. Benjamin	27,025
Gary M. Birch	48,881
William R. Boudreaux	35,796
Steven P. Caltrider	36,467
Paul R. Cantrell	36,470
Charles E. Cohen	34,565
Donald L. Coneglio	30,741
Gregory A. Cox	47,504
Paula K. Davis	47,517
Elizabeth A. Dawalt	44,646
John C. Demeter	30,167
Manisha A. Desai	43,585
Joanne Longo Feeney	35,134
Paul J. Gaylo	36,808
Francis O. Ginah	44,712
Janet A. Gongola	48,436
Amy E. Hamilton	33,894
Frederick D. Hunter	26,915
Thomas E. Jackson	33,064
Charles Joyner	30,466
Gerald P. Keleher	43,707

Attorney Name	Reg. No.
James J. Kelley	41,888
Paul J. Koivuniemi	31,533
Robert E. Lee	27,919
Kirby Lee	47,744
James P. Leeds	35,241
Nelsen L. Lentz	38,537
Douglas K. Norman	33,267
Arleen Palmberg	40,422
Thomas G. Plant	35,784
Edward Prein	37,212
Grant E. Reed	41,264
James J. Sales	33,773
Michael J. Sayles	32,295
Robert L. Sharp	45,609
David M. Stemerick	40,187
Mark J. Stewart	43,936
Robert D. Titus	40,206
Robert C. Tucker	45,165
Tina M. Tucker	47,145
MaCharrl Vomdran-Jones	36,711
Gilbert T. Voy	43,972
Thomas D. Webster	39,872
Lawrence T. Welch	29,487
Alexander Wilson	45,782
Dan L. Wood	48,613

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name **ELI LILLY AND COMPANY**
 Address **ATTN: R. CRAIG TUCKER**
 Address **LILLY CORPORATE CENTER/DC1104**
 City **INDIANAPOLIS** State **INDIANA** ZIP **46285**
 Country Telephone **(317) 433-9829** Fax **(317) 276-3861**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A Petition has been filed for this unsigned inventor

Given Name **Karin** Middle Name **Briner** Family Name **Briner** Suffix **e.g. Jr.**
 Inventor's Signature *Karin Briner* Date **1/9/02**
 Residence: City **Indianapolis** State **IN** Country **USA** Citizenship **Switzerland**
 Address **7649 Pinesprings East Drive**
 Post Office Address **SAME AS ABOVE**
 City **Indianapolis** State **IN** Zip **46256** Country **USA**

☒ Additional inventors are being named on supplement sheet(s) attached hereto.

Please type a plus sign (+) inside this box ☐

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

DECLARATION

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Timothy	Middle Name	Paul	Family Name	Burkholder	Suffix e.g. Jr.	
Inventor's Signature	<i>Timothy Paul Burkholder</i>					Date	1/16/2002
Residence: City	Carmel	State	IN	Country	USA	Citizenship	USA
Post Office Address	13904 Springmill Ponds Circle						
Post Office Address	SAME AS ABOVE						
City	Carmel	State	IN	Zip	46032	Country	USA

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Richard	Middle Name	Gerard	Family Name	Conway	Suffix e.g. Jr.	
Inventor's Signature	<i>Richard Gerard Conway</i>					Date	01/10/2002
Residence: City	Carmel	State	IN	Country	USA	Citizenship	USA
Post Office Address	121 Lark Drive, Apartment C						
Post Office Address	SAME AS ABOVE						
City	Carmel	State	IN	Zip	46032	Country	USA

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Brian	Middle Name	Eugene	Family Name	Cunningham	Suffix e.g. Jr.	
Inventor's Signature	<i>Brian E. Cunningham</i>					Date	1/10/2002
Residence: City	Martinsville	State	IN	Country	USA	Citizenship	USA
Post Office Address	6990 Red Day Road						
Post Office Address	SAME AS ABOVE						
City	Martinsville	State	IN	Zip	46151	Country	USA

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Don	Middle Name	Richard	Family Name	Finley	Suffix e.g. Jr.	
Inventor's Signature	<i>Don Richard Finley</i>					Date	1/9/2002
Residence: City	Greenwood	State	IN	Country	USA	Citizenship	USA
Post Office Address	4644 Macy Drive						
Post Office Address	SAME AS ABOVE						
City	Greenwood	State	IN	Zip	46142	Country	USA

Please type a plus sign (+) inside this box

□



PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98 OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

DECLARATION

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Lawrence	Middle Name	Joseph	Family Name	Heinz	Suffix e.g. Jr.	
Inventor's Signature	<i>Lawrence Joseph Heinz</i>					Date	1/9/2002
Residence: City	Pittsboro	State	IN	Country	USA	Citizenship	USA
Address	212 Fawn Court						
Post Office Address	SAME AS ABOVE						
City	Pittsboro	State	IN	Zip	46167	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Cynthia	Middle Name	Darshini	Family Name	Jesudason	Suffix e.g. Jr.	
Inventor's Signature	<i>Cynthia Darshini Jesudason</i>					Date	1/9/2002
Residence: City	Indianapolis	State	IN	Country	USA	Citizenship	Sri Lanka
Post Office Address	1090 Fleetwood Drive						
Post Office Address	SAME AS ABOVE						
City	Indianapolis	State	IN	Zip	46228	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Daniel	Middle Name	Timothy	Family Name	Kohlman	Suffix e.g. Jr.	
Inventor's Signature	<i>Daniel Timothy Kohlman</i>					Date	1/9/2002
Residence: City	Camby	State	IN	Country	USA	Citizenship	USA
Post Office Address	6281 East Old Otto Court						
Post Office Address	SAME AS ABOVE						
City	Camby	State	IN	Zip	46113	Country	USA

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	Sidney	Middle Name	Xi	Family Name	Liang	Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City	Hamden	State	CT	Country	USA	Citizenship	USA
Address	1404 Aspen Glen Drive						
Post Office Address	SAME AS ABOVE						
City	Hamden	State	CT	Zip	06518	Country	USA

Please type a plus sign (+) inside this box

□



PTO/SB/01 (8-96) (MODIFIED)

DECLARATION

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	Yao-Chang	Middle Name		Family Name	Xu	Suffix e.g. Jr.	
Inventor's Signature	<i>Yaochang Xu</i>					Date	1/10/2002
Residence: City	Fishers	State	IN	Country	USA	Citizenship	Canada
Post Office Address	10815 Timber Springs Drive East						
Post Office Address	SAME AS ABOVE						
City	Fishers	State	IN	Zip	46038	Country	USA

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name		Middle Name		Family Name		Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address	SAME AS ABOVE						
City		State		Zip		Country	

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name		Middle Name		Family Name		Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Address							
Post Office Address	SAME AS ABOVE						
City		State		Zip		Country	

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name		Middle Name		Family Name		Suffix e.g. Jr.	
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address	SAME AS ABOVE						
City		State		Zip		Country	